Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.4.2.12 - nicotinamide phosphoribosyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acne Vulgaris
Study of visfatin expression in acne patients in tissue and serum.
Acquired Immunodeficiency Syndrome
HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.
Acromegaly
A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly.
Adipocytes as a Source of Increased Circulating Levels of Nicotinamide Phosphoribosyltransferase/Visfatin in Active Acromegaly.
Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations.
Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly.
Acute Coronary Syndrome
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes.
Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages.
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Nicotinamide Phosphate Transferase (NAMPT) Increases in Plasma in Patients with Acute Coronary Syndromes, and Promotes Macrophages to M2 Polarization.
The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle.
Acute Kidney Injury
Extracellular signal-regulated kinase 1/2 regulates NAD metabolism during acute kidney injury through microRNA-34a-mediated NAMPT expression.
Acute Lung Injury
Association of PBEF gene polymorphisms with acute lung injury, sepsis, and pneumonia in a northeastern Chinese population.
Augmentation of Pulmonary Epithelial Cell IL-8 Expression and Permeability by Pre-B-cell Colony Enhancing Factor.
Critical role of PBEF expression in pulmonary cell inflammation and permeability.
Emodin alleviates severe acute pancreatitis-associated acute lung injury by decreasing pre-B-cell colony-enhancing factor expression and promoting polymorphonuclear neutrophil apoptosis.
Endothelial eNAMPT Amplifies Preclinical Acute Lung Injury: Efficacy of an eNAMPT-Neutralising mAb.
Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury.
Essential Role of Visfatin in Lipopolysaccharide and Colon Ascendens Stent Peritonitis-Induced Acute Lung Injury.
FK866 attenuates sepsis-induced acute lung injury through c-jun-N-terminal kinase (JNK)-dependent autophagy.
FK866, a Visfatin Inhibitor, Protects Against Acute Lung Injury After Intestinal Ischemia-Reperfusion in Mice via NF-?B Pathway.
Inhibition of Pre-B Cell Colony Enhancing Factor Reduces Lung Injury in Rats Receiving Cardiopulmonary Bypass.
Interactions between PBEF and oxidative stress proteins--a potential new mechanism underlying PBEF in the pathogenesis of acute lung injury.
MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866.
Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration.
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders.
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in LPS-induced neutrophil extracellular traps.
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis.
Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury.
Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome.
Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.
Regulation of inflammatory cytokine expression in pulmonary epithelial cells by Pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism.
Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in rats.
Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown.
Visfatin Exerts Immunotherapeutic Effects in Lipopolysaccharide-Induced Acute Lung Injury in Murine Model.
Visfatin Plays a Significant Role in Alleviating Lipopolysaccharide-Induced Apoptosis and Autophagy Through PI3K/AKT Signaling Pathway During Acute Lung Injury in Mice.
Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions.
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Adenocarcinoma
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Impact of genetic variants of ABCB1, APOB, CAV1, and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients.
Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level.
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by ?-lapachone.
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
Adenocarcinoma of Lung
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Adenoma
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Cystathione ?-Synthase Is Increased in Thyroid Malignancies.
Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level.
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.
Visfatin level in patients with colorectal adenoma.
Visfatin levels in hormonally inactive adrenal adenoma and their association with metabolic parameters
Adenoma, Pleomorphic
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
Adrenal Insufficiency
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Aggressive Periodontitis
Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: An immunohistochemical analysis.
Albuminuria
Adipokines as a link between obesity and chronic kidney disease.
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Role of Nampt-Sirt6 Axis in Renal Proximal Tubules in Extracellular Matrix Deposition in Diabetic Nephropathy.
Alopecia
Assessment of Metabolic Profile and Ischemia-modified Albumin Level in Patients with Alopecia Areata: A Case-Control Study.
Alzheimer Disease
A microdeletion in Alzheimer's disease disrupts NAMPT gene.
Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease.
Alzheimer's disease, ceramide, visfatin and NAD.
Amyotrophic Lateral Sclerosis
Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death.
Anemia
Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Aneurysm
Relationsh?p of spontaneous subarachnoid haemorrhage and cerebral aneurysm to serum Visfatin and Nesfatin-1 levels.
Angina Pectoris
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Angina, Stable
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Angina, Unstable
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Anhedonia
Fasting- and ghrelin-induced food intake is regulated by NAMPT in the hypothalamus.
Anovulation
Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome.
Aortic Aneurysm, Thoracic
Nicotinamide Phosphoribosyltransferase in Smooth Muscle Cells Maintains Genome Integrity, Resists Aortic Medial Degeneration and Is Suppressed in Human Thoracic Aortic Aneurysm Disease.
Aortic Valve Stenosis
Reduced visfatin levels in aortic stenosis increase after aortic valve replacement and may contribute to reverse left ventricular remodelling.
Appendicitis
Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis?
Serum visfatin levels in acute appendicitis.
Arrhythmias, Cardiac
Usefulness of Visfatin as a Predictor of Atrial Fibrillation Recurrence After Ablation Procedure.
Arterial Occlusive Diseases
The role of Visfatin in atherosclerotic peripheral arterial obstructive disease.
Arteritis
Endothelial NLRP3 Inflammasome Activation and Enhanced Neointima Formation in Mice by Adipokine Visfatin.
Arthralgia
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee.
Arthritis
Alterations in adipocyte glucose transporter GLUT4 and circulating adiponectin and visfatin in rat adjuvant induced arthritis.
Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis.
Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate.
Epigenetic regulation of NfatC1 transcription and osteoclastogenesis by nicotinamide phosphoribosyl transferase in the pathogenesis of arthritis.
Nicotinamide mononucleotide-elicited NAMPT signaling activation aggravated adjuvant-induced arthritis in rats by affecting peripheral immune cells differentiation.
Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.
Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP.
Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.
Osteoarthritis and obesity: experimental models.
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Serum Vaspin Levels Are Associated with the Development of Clinically Manifest Arthritis in Autoantibody-Positive Individuals.
The association between clinically suspect arthralgia and adipokines in obese patients.
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
[Serum and synovial adiponectin, resistin, and visfatin levels in rheumatoid arthritis patients : Relation to disease activity.]
Arthritis, Experimental
Alterations in adipocyte glucose transporter GLUT4 and circulating adiponectin and visfatin in rat adjuvant induced arthritis.
Metabolomics Analysis Reveals Therapeutic Effects of ?-Mangostin on Collagen-Induced Arthritis in Rats by Down-regulating Nicotinamide Phosphoribosyltransferase.
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Selective inhibition of PBEF/Visfatin/NAMPT suppresses leukocyte infiltration and cartilage degradation.
Visfatin and Rheumatoid Arthritis: Pathogenetic Implications and Clinical Utility.
Arthritis, Juvenile
Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate.
Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.
Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP.
Arthritis, Psoriatic
Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis.
Obesity in autoimmune diseases: not a passive bystander.
Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity.
Arthritis, Rheumatoid
Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases.
Adipokines in rheumatoid arthritis.
Associations between Adipokines in Arthritic Disease and Implications for Obesity.
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.
Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis.
Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
Epigenetic regulation of NfatC1 transcription and osteoclastogenesis by nicotinamide phosphoribosyl transferase in the pathogenesis of arthritis.
Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Nesfatin-1 and visfatin expression is associated with reduced atherosclerotic disease risk in patients with rheumatoid arthritis.
Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.
Obesity in autoimmune diseases: not a passive bystander.
PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Plasma levels of leptin and visfatin in rheumatoid arthritis patients; is there any relationship with joint damage?
Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis.
Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.
Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
Serum chemerin and visfatin levels and their ratio as possible diagnostic parameters of rheumatoid arthritis.
The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy.
Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis.
Visfatin and adiponectin as novel markers for evaluation of metabolic disturbance in recently diagnosed rheumatoid arthritis patients.
Visfatin and Rheumatoid Arthritis: Pathogenetic Implications and Clinical Utility.
Visfatin as a therapeutic target for rheumatoid arthritis.
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Visfatin: a potential therapeutic target for rheumatoid arthritis.
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
[Serum and synovial adiponectin, resistin, and visfatin levels in rheumatoid arthritis patients : Relation to disease activity.]
Asthma
Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis.
Serum visfatin levels are decreased in schoolchildren with atopic asthma.
Visfatin and ghrelin: can they be forthcoming biomarkers or new drug targets for asthma?
Astrocytoma
Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma ME45 cells.
Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study.
Atherosclerosis
Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque.
Adipocytokines: The pied pipers.
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis.
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure.
Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.
Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis.
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes.
Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice by upregulating visfatin expression.
Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study.
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Dingxin recipe alleviates atherosclerosis injury in ApoE-knockout mice via downregulation of visfatin expression and inhibition of the visfatin-induced inflammatory response.
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
Elevated serum visfatin levels in patients with acute myocardial infarction.
Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke.
Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages.
Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease.
Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis?
Leukocyte Overexpression of Intracellular NAMPT Attenuates Atherosclerosis by Regulating PPAR?-Dependent Monocyte Differentiation and Function.
NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat-induced insulin resistance.
Nicotinamide Phosphate Transferase (NAMPT) Increases in Plasma in Patients with Acute Coronary Syndromes, and Promotes Macrophages to M2 Polarization.
Nicotinamide phosphoribosyltransferase aggravates inflammation and promotes atherosclerosis in ApoE knockout mice.
Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages.
Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.
Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
Polydatin Attenuates Atherosclerosis in ApoE - ? - Mice through PBEF Mediated Reduction of Cholesterol Deposition.
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Serum Amyloid a Promotes Visfatin Expression in Macrophages.
Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study.
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction.
The association between plasma visfatin levels and ED.
The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome.
The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
The role of Visfatin in atherosclerotic peripheral arterial obstructive disease.
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
Visfatin (nicotinomide phosphoribosyltransferase/pre-B cell colony-enhancing factor) activates eNOS via Akt and MAP kinases and improves endothelial function.
Visfatin and Cardio-Cerebro-Vascular Disease.
Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction.
Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cells.
Visfatin Destabilizes Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice.
Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36.
Visfatin Is a Positive Regulator of MCP-1 in Human Adipocytes In Vitro and in Mice In Vivo.
Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly.
VISFATIN PROMOTES FOAM CELL FORMATION BY DYSREGULATING CD36, SRA, ABCA1, AND ABCG1 EXPRESSION IN RAW264.7 MACROPHAGES.
Visfatin, glucose metabolism and vascular disease: a review of evidence.
Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases.
[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
[Novel adipokines: links between obesity and atherosclerosis].
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
[Resistin: a pathogenic factor or a biomarker of metabolic disorders and inflammation?]
[Study on visfatin-induced inflammation and necroptosis via LOX-1 in human umbilical vein endothelial cells].
[The research advances in the relationship between visfatin and cancer].
Atrial Fibrillation
Nicotinamide Phosphoribosyltransferase (Nampt)/Nicotinamide Adenine Dinucleotide (NAD) Axis Suppresses Atrial Fibrillation by Modulating the Calcium Handling Pathway.
Usefulness of Visfatin as a Predictor of Atrial Fibrillation Recurrence After Ablation Procedure.
Visfatin as a predictor of obstructive sleep apnea in atrial fibrillation patients.
Autoimmune Diseases
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Visfatin induces MUC8 and MUC5B expression via p38 MAPK/ROS/NF-?B in human airway epithelial cells.
Axial Spondyloarthritis
Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.
Basal Ganglia Hemorrhage
Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
Behcet Syndrome
Visfatin Levels in Behcet's Disease.
beta-Thalassemia
Relationship between Serum Visfatin and Vascular Inflammation Markers Level in Beta Thalassemia Major Patients.
Bone Diseases
Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.
Brain Diseases
Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.
Brain Injuries
Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation.
Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury.
Neuroprotective effects of FK866 against traumatic brain injury: Involvement of p38/ERK pathway.
Brain Injuries, Traumatic
Change in plasma visfatin level after severe traumatic brain injury.
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Plasma visfatin, associated with a genetic polymorphism -1535C>T, is correlated with C-reactive protein in Chinese Han patients with traumatic brain injury.
Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis.
Visfatin expression and genetic polymorphism in patients with traumatic brain injury.
Brain Ischemia
Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism.
Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury.
Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia.
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation.
Nampt/PBEF/Visfatin Exerts Neuroprotective Effects Against Ischemia/Reperfusion Injury via Modulation of Bax/Bcl-2 Ratio and Prevention of Caspase-3 Activation.
Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury.
Protein Kinase C Epsilon Promotes Cerebral Ischemic Tolerance Via Modulation of Mitochondrial Sirt5.
Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade.
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Breast Neoplasms
Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Circulating leptin, soluble leptin receptor, free leptin index, visfatin and selected leptin and leptin receptor gene polymorphisms in sporadic breast cancer.
Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.
Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion.
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells.
Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer.
Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters.
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer.
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.
Extracellular NAMPT/visfatin causes p53 deacetylation via NAD production and SIRT1 activation in breast cancer cells.
Extracellular NAMPT/Visfatin induces proliferation through ERK1/2 and AKT and inhibits apoptosis in breast cancer cells.
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.
High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival.
Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1.
In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children.
Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Inhibition of Nicotinamide Phosphoribosyltransferase Induces Apoptosis in Estrogen Receptor-Positive MCF-7 Breast Cancer Cells.
Investigating the effect of visfatin on ERalpha phosphorylation (Ser118 and Ser167) and ERE-dependent transcriptional activity.
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
MicroRNA-494 induces breast cancer cell apoptosis and reduces cell viability by inhibition of nicotinamide phosphoribosyltransferase expression and activity.
MiR-613 Promotes Cell Death in Breast Cancer Cells by Downregulation of Nicotinamide Phosphoribosyltransferase and Reduction of NAD.
NAMPT regulates PKM2 nuclear location through 14-3-3?: Conferring resistance to tamoxifen in breast cancer.
NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women.
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.
Significance of Some Non-Invasive Biomarkers in the Early Diagnosis and Staging of Egyptian Breast Cancer Patients.
Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
The association between obesity related adipokines and risk of breast cancer: a meta-analysis.
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.
The NAD(+) salvage pathway modulates cancer cell viability via p73.
Up-regulation of miR-381 inhibits NAD+ salvage pathway and promotes apoptosis in breast cancer cells.
Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages.
Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway.
Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer.
Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer.
Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
Visfatin, breastfeeding, and breast cancer.
Carcinogenesis
A Negative Feedback Loop Between NAMPT and TGF-? Signaling Pathway in Colorectal Cancer Cells.
A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis.
Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma.
Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.
Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin.
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.
FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.
Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma.
Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.
High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.
Intracellular NAD(H) levels control motility and invasion of glioma cells.
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.
Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors.
Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/?-catenin signaling via increasing Axin level.
The Role of Adipokines in Breast Cancer: Current Evidence and Perspectives.
Visfatin levels in hormonally inactive adrenal adenoma and their association with metabolic parameters
[Nicotinamide phosphoribosyltransferase and its roles in cancer].
Carcinoma
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma.
Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment.
Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
Cystathione ?-Synthase Is Increased in Thyroid Malignancies.
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients.
Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin.
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma.
High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.
Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Increased Nicotinamide Phosphoribosyltransferase and Cystathionine-?-Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma.
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.
Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.
miR-181a-2* expression is different amongst carcinomas from the colorectal serrated route.
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
[The expression of nicotinamide phosphoribosyl transferase and vascular endothelial growth factor-A in gastric carcinoma and their clinical significance].
Carcinoma, Acinar Cell
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
Carcinoma, Basal Cell
Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin.
Carcinoma, Ductal
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Carcinoma, Hepatocellular
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Hormonal regulation of visfatin gene in avian Leghorn male hepatoma (LMH) cells.
Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-?B activity and affects Nampt-dependent cell viability in Huh-7 cells.
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
Carcinoma, Non-Small-Cell Lung
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.
NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer.
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Carcinoma, Renal Cell
Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Cardiomegaly
Involvement of TRPC1 in Nampt-induced cardiomyocyte hypertrophy through the activation of ER stress.
Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.
Cardiomyopathies
FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes.
Nicotinamide Phosphoribosyltransferase/Pre-B-Cell Colony Enhancing Factor/Visfatin Plasma Levels and Clinical Outcome in Patients With Dilated Cardiomyopathy.
Cardiomyopathy, Dilated
Association of Nicotinamide Phosphoribosyltransferase (NAMPT) Gene Polymorphisms and of Serum NAMPT Levels with Dilated Cardiomyopathy in a Chinese Population.
[Expression and Initial Mechanism of Nicotinamide Phosphoribosyltransferase (NAMPT) in Dilated Cardiomyopathy].
Cardiotoxicity
Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Cardiovascular Diseases
A novel adipocytokine visfatin protects against H(2)O(2) -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease.
Adipocytokines and metabolic syndrome.
Adipokines as possible new predictors of cardiovascular diseases: a case control study.
An elevated plasma level of visfatin increases the risk of myocardial infarction.
Angiotensin II Type-1 Receptor-JAK/STAT Pathway Mediates the Induction of Visfatin in Angiotensin II-Induced Cardiomyocyte Hypertrophy.
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.
Effect of simvastatin treatment on plasma visfatin levels in obese women.
FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes.
HIF-1? mediates visfatin-induced CTGF expression in vascular endothelial cells.
Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome.
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.
Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin.
NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Serum visfatin levels in women with polycystic ovary syndrome.
The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle.
The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
The metabolic syndrome and adipocytokines.
The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus.
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
Visfatin -948G/T and resistin -420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases.
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.
VISFATIN PROMOTES FOAM CELL FORMATION BY DYSREGULATING CD36, SRA, ABCA1, AND ABCG1 EXPRESSION IN RAW264.7 MACROPHAGES.
Visfatin Promotes Monocyte Adhesion by Upregulating ICAM-1 and VCAM-1 Expression in Endothelial Cells via Activation of p38-PI3K-Akt Signaling and Subsequent ROS Production and IKK/NF-?B Activation.
Visfatin, glucose metabolism and vascular disease: a review of evidence.
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases.
White adipose tissue and cardiovascular disease.
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].
Carotid Artery Diseases
Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.
Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis.
Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study.
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.
Leukocyte Overexpression of Intracellular NAMPT Attenuates Atherosclerosis by Regulating PPAR?-Dependent Monocyte Differentiation and Function.
Nesfatin-1 and visfatin expression is associated with reduced atherosclerotic disease risk in patients with rheumatoid arthritis.
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Carotid Stenosis
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Cerebral Hemorrhage
Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage.
Cerebral Infarction
Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease.
Cerebrovascular Disorders
Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease.
NAMPT and NAMPT-controlled NAD Metabolism in Vascular Repair.
The emerging role of leptin, Adiponectin and Visfatin in Ischemic/Hemorrhagic stroke.
Cervical Intraepithelial Neoplasia
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Cholecystitis
Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis.
Cholecystitis, Acute
Elevated plasma visfatin levels correlate with conversion of laparoscopic cholecystectomy to open surgery in acute cholecystitis.
Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis.
Cholelithiasis
Visfatin and gallstone disease.
Visfatin-a proinflammatory adipokine-in gallstone disease.
[The role of the behaviour food hormones in the development of gallstone disease].
Cholera
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Chondrosarcoma
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway.
Chronic Periodontitis
Comparative Evaluation of Salivary Visfatin Levels in Healthy and Periodontally Diseased Patients before and after Scaling and Root Planing.
Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease.
Effect of Non-surgical Periodontal Therapy on Serum and Salivary Concentrations of Visfatin in Patients with Chronic Periodontitis.
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-?, and Interleukin-6 in Gingival Crevicular Fluid in Patients with Type 2 Diabetes and Chronic Periodontitis.
Evaluation of association between Porphyromonas gingivalis and visfatin levels in chronic periodontitis patients.
Expression of Leptin and Visfatin in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Using Enzyme-Linked Immunosorbent Assay and Real-Time Polymerase Chain Reaction.
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome.
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Periodontitis contributes to aberrant metabolism in type 2 diabetes mellitus rats by stimulating the expression of adipokines.
Salivary Visfatin Concentration in Chronic Periodontitis Patients.
Salivary visfatin concentrations in patients with chronic periodontitis: An analysis before and after periodontal therapy.
The comparison of visfatin levels of gingival crevicular fluid in systemic lupus erythematosus and chronic periodontitis patients with healthy subjects.
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: An immunohistochemical analysis.
Visfatin levels in gingival crevicular fluid and serum before and after non-surgical treatment for periodontal diseases.
Colitis
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
NAD metabolism fuels human and mouse intestinal inflammation.
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat.
Colitis, Ulcerative
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
Serum Visfatin Levels in Ulcerative Colitis.
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Colitis-Associated Neoplasms
NAD metabolism fuels human and mouse intestinal inflammation.
Colonic Neoplasms
Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment.
Visfatin and global histone H3K9me levels in colon cancer.
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Colorectal Neoplasms
A Negative Feedback Loop Between NAMPT and TGF-? Signaling Pathway in Colorectal Cancer Cells.
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Association of plasma visfatin with risk of colorectal cancer: An observational study of Chinese patients.
Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment.
Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients.
Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers.
Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level.
miR-181a-2* expression is different amongst carcinomas from the colorectal serrated route.
NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells.
Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
Resistin and Visfatin Expression in HCT-116 Colorectal Cancer Cell Line.
Role of visfatin in promoting proliferation and invasion of colorectal cancer cells by downregulating SDF-1/CXCR4-mediated miR-140-3p expression.
Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/?-catenin signaling via increasing Axin level.
The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.
Visfatin induces stromal cell-derived factor-1 expression by ?1 integrin signaling in colorectal cancer cells.
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Visfatin level in patients with colorectal adenoma.
Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
Coma
Change in plasma visfatin level after severe traumatic brain injury.
Communicable Diseases
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Regulation of NAMPT in Human Gingival Fibroblasts and Biopsies.
Serum adipokine profiles in Kawasaki disease.
Connective Tissue Diseases
Adipokines in connective tissue diseases.
Corneal Edema
NAD+ precursors protect corneal endothelial cells from UVB-induced apoptosis.
Coronary Artery Disease
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Adipokine gene expression in adipocytes isolated from different fat depots of coronary artery disease patients.
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis.
Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.
Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.
Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population.
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages.
Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.
Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies.
Mechanistic insights into the link between visfatin gene C-1535T polymorphism and coronary artery disease: an in vitro study.
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis.
Serum Levels of Visfatin and Interleukin-6 in Non-Obese Versus Obese Men with Coronary Artery Disease.
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle.
The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome.
The mRNA Expression and Circulating Levels of Visfatin and Their Correlation with Coronary Artery Disease Severity and 25-Hydroxyvitamin D.
Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients.
[Detection of visfatin level of plasma in patients with coronary artery diseases]
Coronary Disease
Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Levels and clinical significance of serum homocysteine (Hcy), high-density lipoprotein cholesterol (HDL-C), vaspin, and visfatin in elderly patients with different types of coronary heart disease.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure.
Coronary Stenosis
Levels and clinical significance of serum homocysteine (Hcy), high-density lipoprotein cholesterol (HDL-C), vaspin, and visfatin in elderly patients with different types of coronary heart disease.
Crohn Disease
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Cysts
Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome.
Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice.
Demyelinating Diseases
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Dengue
Genetic Profiling and Comorbidities of Zika Infection.
Dermatitis, Atopic
Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis.
Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.
Dermatomyositis
Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures.
Diabetes Complications
Role of adipocytokines in predicting the development of diabetes and its late complications.
Diabetes Mellitus
Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.
Adipocytokines and metabolic syndrome.
An evaluation of visfatin levels in obese subjects.
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Assessment of Salivary Adipokines Resistin, Visfatin, and Ghrelin as Type 2 Diabetes Mellitus Biomarkers.
Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes.
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle.
Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Consumption of extra-virgin olive oil rich in phenolic compounds improves metabolic control in patients with type 2 diabetes mellitus: a possible involvement of reduced levels of circulating visfatin.
Depletion of NAD pool contributes to impairment of endothelial progenitor cell mobilization in diabetes.
Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration.
Differential Expression of Human N-Alpha-Acetyltransferase 40 (hNAA40), Nicotinamide Phosphoribosyltransferase (NAMPT) and Sirtuin-1 (SIRT-1) Pathway in Obesity and T2DM: Modulation by Metformin and Macronutrient Intake.
Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes.
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Expression of Leptin and Visfatin in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Using Enzyme-Linked Immunosorbent Assay and Real-Time Polymerase Chain Reaction.
Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans.
Increased insulin sensitivity in individuals with neurofibromatosis type 1.
Increased levels and adipose tissue expression of visfatin in morbidly obese women. The relationship with pro-inflammatory cytokines.
Insulin-like effects of visfatin on human osteoblasts.
Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Maternal visfatin concentration in normal pregnancy.
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Nampt and its potential role in inflammation and type 2 diabetes.
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Plasma visfatin concentrations in subjects with type 1 diabetes mellitus.
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus.
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus.
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Rapid and sensitive detection of Nampt (PBEF/visfatin) in human serum using an ssDNA aptamer-based capacitive biosensor.
Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.
Relation of visfatin to cardiovascular risk factors and adipocytokines in patients with impaired fasting glucose.
Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus.
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus.
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion.
The comparison of serum vaspin and visfatin concentrations in obese and normal weight women.
The correlation between insulin-like growth factor 1 (IGF-1) and novel adipocytokines in postmenopausal women: A population-based study.
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
The metabolic syndrome and adipocytokines.
The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
TNF-alpha alters visfatin and adiponectin levels in human fat.
Visfatin concentrations in patients with endometrial cancer.
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NF?B and JNK in human abdominal subcutaneous adipocytes.
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Visfatin Stimulates a Cellular Renin-Angiotensin System in Cultured Rat Mesangial Cells.
Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions.
White adipose tissue and cardiovascular disease.
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
[Visfatin level after laparoscopic Roux-en-Y gastric bypass surgery in patients with Type 2 diabetes].
Diabetes Mellitus, Type 1
Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration.
Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.
Low placental visfatin expression is related to impaired glycaemic control and fetal macrosmia in pregnancies complicated by type 1 diabetes.
Omentin-1 and NAMPT serum concentrations are higher and CK-18 levels are lower in children and adolescents with type 1 diabetes when compared to healthy age, sex and BMI matched controls.
Plasma visfatin concentrations in subjects with type 1 diabetes mellitus.
Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Diabetes Mellitus, Type 2
A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity.
A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes.
Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Assessment of Salivary Adipokines Resistin, Visfatin, and Ghrelin as Type 2 Diabetes Mellitus Biomarkers.
Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes.
Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome.
Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Consumption of extra-virgin olive oil rich in phenolic compounds improves metabolic control in patients with type 2 diabetes mellitus: a possible involvement of reduced levels of circulating visfatin.
Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.
Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes.
Depletion of NAD pool contributes to impairment of endothelial progenitor cell mobilization in diabetes.
Determinants of visfatin in type 2 diabetes patients with diabetic kidney disease: Relationship to inflammation, adiposity and undercarboxylated osteocalcin.
Differential Expression of Human N-Alpha-Acetyltransferase 40 (hNAA40), Nicotinamide Phosphoribosyltransferase (NAMPT) and Sirtuin-1 (SIRT-1) Pathway in Obesity and T2DM: Modulation by Metformin and Macronutrient Intake.
Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism.
Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes.
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-?, and Interleukin-6 in Gingival Crevicular Fluid in Patients with Type 2 Diabetes and Chronic Periodontitis.
Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Expression of Leptin and Visfatin in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Using Enzyme-Linked Immunosorbent Assay and Real-Time Polymerase Chain Reaction.
Extracellular Visfatin Activates Gluconeogenesis in HepG2 Cells Through the Classical PKA/CREB-Dependent Pathway.
Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population.
Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment.
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Increased insulin sensitivity in individuals with neurofibromatosis type 1.
Insulin-like effects of visfatin on human osteoblasts.
Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment.
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Nampt and its potential role in inflammation and type 2 diabetes.
Nampt: linking NAD biology, metabolism and cancer.
Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation.
Perinatal circulating visfatin levels in intrauterine growth restriction.
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass.
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus.
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Rapid and sensitive detection of Nampt (PBEF/visfatin) in human serum using an ssDNA aptamer-based capacitive biosensor.
Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast.
Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.
Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Resveratrol attenuates visfatin and vaspin genes expression in adipose tissue of rats with type 2 diabetes.
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Saponins as adipokines modulator: A possible therapeutic intervention for type 2 diabetes.
Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus.
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus.
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes.
The -1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects.
The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion.
The comparison of serum vaspin and visfatin concentrations in obese and normal weight women.
The correlation between insulin-like growth factor 1 (IGF-1) and novel adipocytokines in postmenopausal women: A population-based study.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
The Impact of Type 2 Diabetes on Circulating Adipokines in Patients with Metabolic Syndrome.
The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.
The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients.
Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NF?B and JNK in human abdominal subcutaneous adipocytes.
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Visfatin Stimulates a Cellular Renin-Angiotensin System in Cultured Rat Mesangial Cells.
Visfatin Triggers Anorexia and Body Weight Loss through Regulating the Inflammatory Response in the Hypothalamic Microglia.
Visfatin, TNF-alpha and IL-6 mRNA Expression is Increased in Mononuclear Cells from Type 2 Diabetic Women.
Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.
Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions.
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
[Visfatin level after laparoscopic Roux-en-Y gastric bypass surgery in patients with Type 2 diabetes].
Diabetes, Gestational
A clinical research study on the respective relationships between visfatin and human fetuin A and pregnancy outcomes in gestational diabetes mellitus.
Adipokines in gestational diabetes.
Are adipokines associated with gestational diabetes mellitus?
Association between circulating visfatin and gestational diabetes mellitus: a systematic review and meta-analysis.
Central visfatin potentiates glucose-stimulated insulin secretion and ?-cell mass without increasing serum visfatin levels in diabetic rats.
Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus.
Circulating visfatin levels in the second and third trimester of pregnancies with gestational diabetes: a systematic review.
Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus.
Decreased plasma visfatin concentrations in women with gestational diabetes mellitus.
Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance.
Gestational diabetes is associated with high energy and saturated fat intakes and with low plasma visfatin and adiponectin levels independent of prepregnancy BMI.
Increased visfatin concentrations in women with gestational diabetes mellitus.
Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus.
Maternal and cord blood apelin, resistin and visfatin levels in gestational diabetes mellitus.
Maternal leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha in normal and gestational diabetes.
Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus.
Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM.
Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus.
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Relationship of maternal serum resistin and visfatin levels with gestational diabetes mellitus.
Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus.
Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes.
Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy.
The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes.
The role of visfatin (PBEF/Nampt) in pregnancy complications.
The role of visfatin in pathogenesis of gestational diabetes (GDM).
The Role of Visfatin in the Pathogenesis of Gestational Diabetes Mellitus.
Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester.
Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue.
Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight.
Visfatin level and gestational diabetes mellitus: a systematic review and meta-analysis.
Visfatin response to glucose is reduced in women with gestational diabetes mellitus.
[Correlation between the expression of gastrocolic omentum visfatin mRNA and gestational diabetes mellitus]
[Role of visfatin in the pathogenesis of gestational diabetes mellitus and its relationship with insulin resistance].
[The expression of visfatin in placenta in women with gestational diabetes mellitus].
Diabetic Cardiomyopathies
Nampt Potentiates Antioxidant Defense in Diabetic Cardiomyopathy.
Diabetic Ketoacidosis
Evaluation of adipokines, adiponectin, visfatin, and omentin, in uncomplicated type I diabetes patients before and after treatment of diabetic ketoacidosis.
Diabetic Nephropathies
Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy.
Advances in the proinflammatory effects of visfatin and its relationship with diabetic kidney disease.
Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes.
Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy.
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Correlation Between Circulating Visfatin and Nitric Oxide Metabolites Levels in Patients With Diabetic Nephropathy.
Determinants of visfatin in type 2 diabetes patients with diabetic kidney disease: Relationship to inflammation, adiposity and undercarboxylated osteocalcin.
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory-fibrosis through the NF-?B p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory-fibrosis by inhibiting endogenous Nampt.
Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.
Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.
OS 36-03 E-BOX CpG HYPOMETHYLATION OF NMN-PRODUCING ENZYME NAMPT IN PROXIMAL TUBULES ENABLES CONSTANT SUPPLY OF NMN FROM TUBULES TO GLOMERULI, WHICH IS DISRUPTED IN DIABETIC NEPHROPATHY.
Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients.
Role of Nampt-Sirt6 Axis in Renal Proximal Tubules in Extracellular Matrix Deposition in Diabetic Nephropathy.
Study of Visfatin Level in Type 1 Diabetic Children and Adolescents.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
The role of visfatin in diabetic nephropathy.
Visfatin is upregulated in type-2 diabetic rats and targets renal cells.
Visfatin levels are decreased in advanced stages of diabetic nephropathy.
Visfatin Stimulates a Cellular Renin-Angiotensin System in Cultured Rat Mesangial Cells.
Visfatin: a new player in mesangial cell physiology and diabetic nephropathy.
Diabetic Neuropathies
Relationship between diabetic polyneuropathy, serum visfatin, and oxidative stress biomarkers.
Diabetic Retinopathy
Expression of visfatin in the diabetic rat retina.
Serum and vitreous levels of visfatin in patients with diabetic retinopathy.
Visfatin promotes angiogenesis of RF/6A cells through upregulation of VEGF/VEGFR-2 under high-glucose conditions.
Dyslipidemias
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus.
Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis.
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Encephalitis
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Endometrial Hyperplasia
High level of visfatin and the activation of Akt and ERK1/2 signaling pathways are associated with endometrium malignant transformation in polycystic ovary syndrome.
Endometrial Neoplasms
Circulating Serum Level of Visfatin in Patients with Endometrial Cancer.
Clinical significance of serum adiponectin and visfatin levels in endometrial cancer.
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis.
Visfatin concentrations in patients with endometrial cancer.
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Visfatin, a potential biomarker and prognostic factor for endometrial cancer.
[The research advances in the relationship between visfatin and cancer].
Endotoxemia
Distinct effects of Nampt inhibition on mild and severe models of lipopolysaccharide-induced myocardial impairment.
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
The sensitivity of adipose tissue visfatin mRNA expression to lipopolysaccharide-induced endotoxemia is increased by ovariectomy in female rats.
Epilepsy
Acute Phase Serum Leptin, Adiponectin, Interleukin-6, and Visfatin Are Altered in Chinese Children With Febrile Seizures: A Cross-Sectional Study.
Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches.
The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy.
Erectile Dysfunction
The association between plasma visfatin levels and ED.
Esophageal Squamous Cell Carcinoma
Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma.
Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.
Essential Hypertension
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure.
Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis.
Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients.
[Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female].
Familial Mediterranean Fever
Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis?
Fatty Liver
A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1.
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease.
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.
Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity.
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome.
Effect of curcumin on visfatin and zinc-?2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.
Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway.
Obesity Potentiates Esophageal Squamous Cell Carcinoma Growth and Invasion by AMPK-YAP Pathway.
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease.
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
[Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease]
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Fatty Liver, Alcoholic
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Fetal Growth Retardation
Perinatal circulating visfatin levels in intrauterine growth restriction.
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
Uteroplacental insufficiency after bilateral uterine artery ligation in the rat: impact on postnatal glucose and lipid metabolism and evidence for metabolic programming of the offspring by sham operation.
[Relationship of adiponectin and visfatin with fetus intrauterine growth]
Fetal Macrosomia
Low placental visfatin expression is related to impaired glycaemic control and fetal macrosmia in pregnancies complicated by type 1 diabetes.
[Relationship of adiponectin and visfatin with fetus intrauterine growth]
Fibrosarcoma
Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation.
Frontotemporal Lobar Degeneration
Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration.
Gallstones
Visfatin-a proinflammatory adipokine-in gallstone disease.
Gastritis
Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement.
Gingivitis
Comparative Evaluation of Salivary Visfatin Levels in Healthy and Periodontally Diseased Patients before and after Scaling and Root Planing.
Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation.
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
The Role of Visfatin (Adipocytokine) Biomarker in Oral Health and Diseases among Nonobese Indian Population: A Proteomic Assay.
Visfatin levels in gingival crevicular fluid and serum before and after non-surgical treatment for periodontal diseases.
Glioblastoma
Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.
NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.
Glioma
Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.
Genotype-targeted local therapy of glioma.
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Insulin receptor substrate 1 gene expression is strongly up-regulated by HSPB8 silencing in U87 glioma cells.
Intracellular NAD(H) levels control motility and invasion of glioma cells.
Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
Long noncoding RNA GACAT3 promotes glioma progression by sponging miR-135a.
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation.
NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance.
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.
NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Silencing of NAMPT leads to up-regulation of insulin receptor substrate 1 gene expression in U87 glioma cells.
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
Glucose Intolerance
ACTIVATION OF HYPOTHALAMIC NPY, AgRP, MC4R, AND IL-6 mRNA LEVELS IN YOUNG LEWIS RATS WITH EARLY-LIFE DIET-INDUCED OBESITY.
Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Gender dimorphic increase in RBP-4 and NGAL in children born after IVF: an epigenetic phenomenon?
Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment.
Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Relationship of maternal serum resistin and visfatin levels with gestational diabetes mellitus.
Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus.
Serum visfatin is elevated in Chinese women with polycystic ovary syndrome, but might not be a reliable predictor of their glucose intolerance.
Short-term effects induced by nicotinamide in ovariectomized females.
Glucose Metabolism Disorders
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Goiter, Nodular
Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies.
Graves Disease
Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies.
Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Hashimoto Disease
Obesity in autoimmune diseases: not a passive bystander.
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Head and Neck Neoplasms
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
Hearing Loss
Environmental enrichment modulates silent information regulator 1 (SIRT1) activity to attenuate central presbycusis in a rat model of normal aging.
Heart Arrest
Plasma Adipokines in Patients Resuscitated from Cardiac Arrest: Difference of Visfatin between Survivors and Nonsurvivors.
Heart Failure
Angiotensin II Type-1 Receptor-JAK/STAT Pathway Mediates the Induction of Visfatin in Angiotensin II-Induced Cardiomyocyte Hypertrophy.
Both gain and loss of Nampt function promote pressure overload-induced heart failure.
Monocyte-derived extracellular Nampt-dependent biosynthesis of NAD(+) protects the heart against pressure overload.
Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure.
Serum concentration of visfatin is decreased in patients with chronic heart failure.
[Expression and Initial Mechanism of Nicotinamide Phosphoribosyltransferase (NAMPT) in Dilated Cardiomyopathy].
Hematologic Neoplasms
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
Hepatitis
A key role for Pre-B cell colony-enhancing factor in experimental hepatitis.
Suppression of SIRT1 activity in noncancerous tissues of HCC: possible association with non-B non-C hepatitis pathogenesis.
Hepatitis B
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis.
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B.
Hepatitis B, Chronic
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
Hepatitis C
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Hepatitis C, Chronic
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patients.
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Preliminary study of the level of visfatin and the relationship with insulin resistance in Chinese patients with chronic hepatitis C.
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.
Visfatin serum levels in chronic hepatitis C patients.
Hidradenitis Suppurativa
Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa.
Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study.
Hirsutism
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Plasma Visfatin Levels in Adolescents with Polycystic Ovary Syndrome: A Prospective Case-Control Study.
Hodgkin Disease
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Hyperandrogenism
Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome.
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
Hypercholesterolemia
Hypercholesterolemia induces adipose dysfunction in conditions of obesity and nonobesity.
Hyperglycemia
Combined SIRT3 and SIRT5 deletion is associated with inner retinal dysfunction in a mouse model of type 1 diabetes.
Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration.
Hyperglycemia-reduced NAD+ biosynthesis impairs corneal epithelial wound healing in diabetic mice.
in vivo Suppression of Visfatin by Oral Glucose Uptake: Evidence for a Novel Incretin-Like Effect by Glucagon-Like Peptide-1 (GLP-1).
Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens.
Leptin Is Associated With Persistence of Hyperglycemia in Acute Pancreatitis: A Prospective Clinical Study.
Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients.
Hyperinsulinism
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Hyperlipidemias
Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin.
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
Impact of Chicory?Supplemented Diet on HMG?CoA Reductase, Acetyl?CoA Carboxylase, Visfatin and Anti?Oxidant Status in Triton WR?1339?Induced Hyperlipidemia
Hyperlipoproteinemia Type II
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Hyperostosis
Increased serum leptin and visfatin levels in patients with diffuse idiopathic skeletal hyperostosis: a comparative study.
Hyperostosis, Diffuse Idiopathic Skeletal
Increased serum leptin and visfatin levels in patients with diffuse idiopathic skeletal hyperostosis: a comparative study.
Hypersensitivity
CA1 Nampt knockdown recapitulates hippocampal cognitive phenotypes in old mice which nicotinamide mononucleotide improves.
Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells.
Hypertension
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Adipokine Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy.
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure.
Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients.
Associations of Apelin, Visfatin, and Urinary 8-Isoprostane With Severe Hypertension in African Americans: The MH-GRID Study.
Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats.
Coexistence of obstructive sleep apnea and telomerase activity, concentration of selected adipose tissue hormones and vascular endothelial function in patients with arterial hypertension.
Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension.
Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2?.
In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children.
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
MC4R Variant rs17782313 Associates With Increased Levels of DNAJC27, Ghrelin, and Visfatin and Correlates With Obesity and Hypertension in a Kuwaiti Cohort.
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase.
NAMPT/SIRT1 Attenuate Ang II-Induced Vascular Remodeling and Vulnerability to Hypertension by Inhibiting the ROS/MAPK Pathway.
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension.
Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis.
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Visfatin and Cardio-Cerebro-Vascular Disease.
Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis.
Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy.
Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients.
Visfatin, a potential biomarker and prognostic factor for endometrial cancer.
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
[Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female].
Hypertension, Pregnancy-Induced
Adipokine Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy.
Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.
Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Hypertension, Pulmonary
Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2?.
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase.
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.
Hypertension, Renovascular
Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension.
Hyperthyroidism
Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Effect of restoration of euthyroidism on visfatin concentrations and body composition in women.
Insulin resistance and its correlation with chemerin and visfatin in Saudi patients with hyperthyroidism.
Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalisation of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin.
Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations.
Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Hypertriglyceridemia
Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients.
Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.
Hypertrophy, Left Ventricular
Reduced visfatin levels in aortic stenosis increase after aortic valve replacement and may contribute to reverse left ventricular remodelling.
The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients.
The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients.
Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy.
Hypoglycemia
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
Hypophosphatemia
Hepatectomy-related hypophosphatemia: a novel phosphaturic factor in the liver-kidney axis.
Hypophosphatemia after Hepatectomy or Pancreatectomy: Role of the Nicotinamide Phosphoribosyltransferase.
Hypothyroidism
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalisation of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations.
Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Visfatin, Leptin, and TNF-?: Interrelated Adipokines in Insulin-Resistant Clinical and Subclinical Hypothyroidism.
Immune System Diseases
An elevated plasma level of visfatin increases the risk of myocardial infarction.
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders.
Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis.
Infarction, Middle Cerebral Artery
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade.
Infections
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Adenovirus36 infection expresses cellular APMI and Visfatin genes in overweight Uygur individuals.
Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Genetic Profiling and Comorbidities of Zika Infection.
Inhibition of pre-B cell colony-enhancing factor (PBEF/NAMPT/visfatin) decreases the ability of human neutrophils to generate reactive oxidants but does not impair bacterial killing.
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Intracellular survival of Staphylococcus aureus in adipocyte-like differentiated 3T3-L1 cells is glucose dependent and alters cytokine, chemokine, and adipokine secretion.
Maternal plasma visfatin in preterm labor.
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Nicotinamide phosphoribosyltransferase and intra-amniotic inflammation in preterm prelabor rupture of membranes.
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Pre-B-cell colony-enhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells.
Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes.
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
Visfatin regulates the terminal processes of human labour and delivery via activation of the nuclear factor-?B pathway.
Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.
Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.
Weighted Gene Co-Expression Network Analysis Identifies Key Modules and Hub Genes Associated with Mycobacterial Infection of Human Macrophages.
Inflammatory Bowel Diseases
Adipocytokines: The pied pipers.
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients.
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
Obesity in autoimmune diseases: not a passive bystander.
Serum Visfatin Levels in Ulcerative Colitis.
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Influenza, Human
Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice.
Insulin Resistance
A novel single-nucleotide polymorphism of the visfatin gene and its associations with performance traits in the chicken.
A single bout of downhill running transiently increases HOMA-IR without altering adipokine response in healthy adult women.
ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity.
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Adipocytokines and bone mineral density in adolescent female athletes.
Adipocytokines and the metabolic complications of obesity.
Adipokines and ?-cell dysfunction in normoglycemic women with previous gestational diabetes mellitus.
Adipokines and cardiometabolic function: How are they interlinked?
Adipokines and etiopathology of metabolic disorders.
Adipokines and insulin resistance.
Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis.
Adiponectin and visfatin levels in extremely low birth weight infants; they are also at risk for insulin resistance.
Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea.
Adipose tissue and its role in organ crosstalk.
Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment.
Aerobic exercise training-induced decrease in plasma visfatin and insulin resistance in obese female adolescents.
Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease.
An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity.
Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance.
Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
Association of adipokines with obesity in children and adolescents.
Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis Vulgaris.
Association of Apolipoprotein E Polymorphism with Adipokines and Cardiovascular Disease Risk in Rheumatoid Arthritis Patients.
Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.
Association of circulating visfatin concentrations with insulin resistance and low-grade inflammation after dietary energy restriction in Spanish obese non-diabetic women: Role of body composition changes.
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity.
C358A missense polymorphism of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) and visfatin levels in obese females.
Central visfatin potentiates glucose-stimulated insulin secretion and ?-cell mass without increasing serum visfatin levels in diabetic rats.
Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy.
Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus.
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus.
Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes.
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome.
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle.
Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
Circulating visfatin levels in healthy preterm infants are independently associated with high-density lipoprotein cholesterol levels and dietary long-chain polyunsaturated fatty acids.
Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification.
Correlation of serum adipocytokine levels with glycolipid metabolism and inflammatory factors in obese patients with periodontal disease.
Correlations between the expression of the insulin sensitizing hormones, adiponectin, visfatin, and omentin, and the appetite regulatory hormone, neuropeptide Y and its receptors in subcutaneous and visceral adipose tissues.
Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus.
CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes.
Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes.
Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome.
Dietary Blueberry and Soluble Fiber Improve Serum Antioxidant and Adipokine Biomarkers and Lipid Peroxidation in Pregnant Women with Obesity and at Risk for Gestational Diabetes.
Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths.
Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function.
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer.
Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin.
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Effect of restoration of euthyroidism on visfatin concentrations and body composition in women.
Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Effect of substituting saturated with monounsaturated fatty acids on serum visfatin levels and insulin resistance in overweight women: A randomized cross-over clinical trial.
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Effects of different levels of physical inactivity on plasma visfatin in healthy normal-weight men.
Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats.
Effects of fatty acid regulation on visfatin gene expression in adipocytes.
Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children.
Effects of high-fat high-sucrose feeding, energy restriction, and trans-10,cis-12 conjugated linoleic acid on visfatin and apelin in hamsters.
Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: A 48-week comparative study.
Effects of visfatin gene polymorphism RS4730153 on exercise-induced weight loss of obese children and adolescents of Han Chinese.
Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes.
Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance.
Elevated visfatin levels in obese children are related to proinflammatory factors.
Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.
Estrogens induce visfatin expression in 3T3-L1 cells.
Evaluation of adipocytokines in obese children with insulin resistance.
Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome.
Evidence for serum visfatin but not adiponectin or resistin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome.
Extracellular Visfatin Activates Gluconeogenesis in HepG2 Cells Through the Classical PKA/CREB-Dependent Pathway.
Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population.
Glucagon-like Peptide-1 Upregulates Visfatin Expression in 3T3-L1 Adipocytes.
High birth weight and early postnatal weight gain protect obese children and adolescents from truncal adiposity and insulin resistance: metabolically healthy but obese subjects?
Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment.
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Impact of Low Frequency Electro-acupuncture on Glucose and Lipid Metabolism in Unmarried PCOS Women: A Randomized Controlled Trial.
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome.
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Importance of Adipose Tissue NAD+ Biology in Regulating Metabolic Flexibility.
Increase in visfatin after weight loss induced by gastroplastic surgery.
Increased insulin sensitivity in individuals with neurofibromatosis type 1.
Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.
Increased visfatin concentrations in women with gestational diabetes mellitus.
Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin.
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Insulin resistance and its correlation with chemerin and visfatin in Saudi patients with hyperthyroidism.
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors.
Intrauterine Growth Restriction: the controversial role of perinatal adipocytokines in the prediction of metabolic adult disease.
Lack of effect of a moderate hypocaloric diet on visfatin levels in morbid obese patients: relationship with insulin resistance.
Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease.
Long-term high-fat diet links the regulation of the insulin-sensitizing fibroblast growth factor-21 and visfatin.
Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery.
Macrostemonoside A promotes visfatin expression in 3T3-L1 cells.
Maternal plasma visfatin in preterm labor.
Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus.
Maternal visfatin concentration in normal pregnancy.
Mechanisms involved in altered bone metabolism in diabetes: a narrative review.
Molecular characteristics of serum visfatin and differential detection by immunoassays.
Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment.
mRNA abundance of adiponectin and its receptors, leptin and visfatin and of G-protein coupled receptor 41 in five different fat depots from sheep.
NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat-induced insulin resistance.
NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice.
Nicotinamide phosphoribosyltransferase enhances beta cell expansion during pregnancy.
Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice.
Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.
Obesity and obstructive sleep apnea syndrome.
Obesity Is Associated With Low NAD(+)/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins.
Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome.
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
Perinatal circulating visfatin levels in intrauterine growth restriction.
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM.
Plasma levels of lipopolysaccharide correlate with insulin resistance in HIV patients.
Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
Plasma visfatin and adiponectin concentrations in physically active adolescent girls: relationships with insulin sensitivity and body composition variables.
Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome.
Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children.
Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.
Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices.
Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalisation of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
Plasma visfatin is increased after high-intensity exercise.
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome.
Portal and systemic levels of visfatin in morbidly obese subjects undergoing bariatric surgery.
Preliminary study of the level of visfatin and the relationship with insulin resistance in Chinese patients with chronic hepatitis C.
Prothrombotic state, cardiovascular, and metabolic syndrome risk factors in prepubertal children born large for gestational age.
Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
Regulation of adipokine secretion by n-3 fatty acids.
Relation of chemokines to BMI and insulin resistance at ages 18-21.
Relationship between 11?-HSD2 mRNA and insulin sensitivity in term small-for-gestational age neonates after birth.
Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans.
Relationship of visfatin level to pancreatic endocrine hormone level, HOMA-IR index, and HOMA ?-cell index in overweight women who performed hydraulic resistance exercise.
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Resistin, visfatin and insulin sensitivity in selected phases of annual training cycle of triathletes.
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children.
Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Secretory function of adipose tissue.
Serum concentration of visfatin is decreased in patients with chronic heart failure.
Serum levels of the adipokine visfatin are increased in pre-eclampsia.
Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity.
Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome.
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
Serum visfatin concentration and its relationship with sex hormones in obese Saudi women.
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol.
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Serum visfatin in Asian women with polycystic ovary syndrome.
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa.
Serum visfatin levels in women with polycystic ovary syndrome.
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Serum visfatin, resistin and IL-18 in A group of Egyptian obese diabetic and non diabetic individuals.
Short-term regulation of Visfatin release in vivo by oral lipid ingestion and in vitro by fatty acid stimulation.
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
Skeletal muscle overexpression of nicotinamide phosphoribosyl transferase in mice coupled with voluntary exercise augments exercise endurance.
Sleep Deficiency is a Modifiable Risk Factor for Obesity and Cognitive Impairment and Associated with Elevated Visfatin.
Spleen-yang-deficiency patients with polycystic ovary syndrome have higher levels of visfatin.
The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo.
The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile.
The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus.
The effects of genistein supplementation on fructose induced insulin resistance, oxidative stress and inflammation.
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing.
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
The metabolic syndrome: metabolic changes with vascular consequences.
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
The relationship between serum visfatin, adiponectin, and insulin sensitivity markers in neonates after birth.
The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance.
The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients.
The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity.
The role of adipokines in skeletal muscle inflammation and insulin sensitivity.
The role of adipokines in the pathogenesis of gestational diabetes mellitus.
The role of infiltrating immune cells in dysfunctional adipose tissue.
The role of leptin, soluble leptin receptor, adiponectin and visfatin in insulin sensitivity in preterm born children in prepubertal ages.
The role of the adipocytokines vaspin and visfatin in vascular endothelial function and insulin resistance in obese children.
The up-regulation of markers of adipose tissue fibrosis by visfatin in pre-adipocytes as well as obese children and adolescents.
The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis.
The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects.
Therapeutic perspectives of adipocytokines.
TNF-alpha alters visfatin and adiponectin levels in human fat.
Transition period-related changes in the abundance of the mRNAs of adiponectin and its receptors, of visfatin, and of fatty acid binding receptors in adipose tissue of high-yielding dairy cows.
Visceral fat resection in humans: Effect on insulin sensitivity, beta-cell function, adipokines and inflammatory markers.
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
VISFATIN (NAMPT) Improves In Vitro IGF1-Induced Steroidogenesis and IGF1 Receptor Signaling Through SIRT1 in Bovine Granulosa Cells.
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.
Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study.
Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation.
Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS.
Visfatin and SREBP-1c mRNA Expressions and Serum Levels Among Egyptian Women with Polycystic Ovary Syndrome.
Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester.
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients.
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Visfatin Induces Inflammation and Insulin Resistance via the NF-?B and STAT3 Signaling Pathways in Hepatocytes.
Visfatin inhibits apoptosis of pancreatic {beta}-cell line, MIN6, via the mitogen-activated protein kinase/phosphoinositide 3-kinase pathway.
Visfatin is an adipokine, but it is not regulated by thiazolidinediones.
Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
Visfatin is involved in TNF?-mediated insulin resistance via an NAD(+)/Sirt1/PTP1B pathway in 3T3-L1 adipocytes.
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Visfatin is upregulated in type-2 diabetic rats and targets renal cells.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Visfatin regulates genes related to lipid metabolism in porcine adipocytes.
Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Visfatin, TNF-alpha and IL-6 mRNA Expression is Increased in Mononuclear Cells from Type 2 Diabetic Women.
Visfatin: a new player in mesangial cell physiology and diabetic nephropathy.
Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study.
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
[Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome]
[Effect of flavonoids from Abelmoschus manihot on proliferation, differentiation of 3T3-L1 preadipocyte and insulin resistance].
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
[Effects of visfatin gene overexpression on insulin sensitivity in the insulin-resistant rats induced by high-fat diet]
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[New evidence for the pathogenesis of obesity: adipokines are adipose tissue hormone].
[Novel adipokines: links between obesity and atherosclerosis].
[Resistin: a pathogenic factor or a biomarker of metabolic disorders and inflammation?]
[Role of visfatin in the pathogenesis of gestational diabetes mellitus and its relationship with insulin resistance].
[The research advances in the relationship between visfatin and cancer].
[Visfatin in obese patients, relation with cardiovascular risk factors, a cross sectional study.]
[Visfatin level after laparoscopic Roux-en-Y gastric bypass surgery in patients with Type 2 diabetes].
[Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.]
[Visfatin promotes production of monocyte chemotactic protein-1 and interleukin-6 in human endothelial cells via insulin receptor]
Insulinoma
Visfatin Protects Rat Pancreatic ?-cells against IFN-?-Induced Apoptosis through AMPK and ERK1/2 Signaling Pathways.
Intervertebral Disc Degeneration
Small Extracellular Vesicles Derived from Adipocytes Attenuate Intervertebral Disc Degeneration in Rats by Rejuvenating Senescent Nucleus Pulposus Cells and Endplate Cells by Delivering Exogenous NAMPT.
Visfatin promotes intervertebral disc degeneration by inducing IL-6 expression through the ERK/JNK/p38 signalling pathways.
Intracranial Aneurysm
Relationsh?p of spontaneous subarachnoid haemorrhage and cerebral aneurysm to serum Visfatin and Nesfatin-1 levels.
Ischemic Stroke
Adipokines in neurovascular diseases.
Association of serum vaspin, apelin, and visfatin levels and stroke risk in a Chinese case-control study.
Change in plasma visfatin level after severe traumatic brain injury.
Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke.
Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia.
NAMPT as a Therapeutic Target against Stroke.
Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury.
Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke.
Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway.
Notoginsenoside R1 activates the NAMPT-NAD+-SIRT1 cascade to promote postischemic angiogenesis by modulating Notch signaling.
Pre-B-cell colony-enhancing factor protects against apoptotic neuronal death and mitochondrial damage in ischemia.
Prognostic significance of plasma visfatin levels in patients with ischemic stroke.
Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade.
Selected adipose tissue hormones in the blood of patients with ischaemic cerebral stroke.
Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis.
Visfatin and Cardio-Cerebro-Vascular Disease.
Joint Diseases
Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases.
Kidney Diseases
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients.
Kidney Failure, Chronic
Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.
Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Kidney Neoplasms
Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Leiomyoma
Differential expression of visfatin, leptin, stromal cell derived factor-1?, endothelial nitric oxide synthase, and vascular endothelial growth factor in human leiomyomas.
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Leiomyosarcoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Leukemia
APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
NAD as a genotype-specific drug target.
NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.
Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.
Visfatin concentrations in children with leukemia before and after stem cell transplantation.
Leukemia, Lymphocytic, Chronic, B-Cell
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.
On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Suppression of NAMPT expression enhances the sensitivity of K562 cells to imatinib and its relative mechanism].
Leukemia, Myeloid
The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.
Leukemia, Myeloid, Acute
Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.
Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL-17.
Liver Cirrhosis
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Splanchnic concentrations and postprandial release of visceral adipokines.
The Effectiveness of Mediterranean Diet in Nonalcoholic Fatty Liver Disease Clinical Course: An Intervention Study.
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
[Effect of visfatin on the expression of basic fibroblast growth factor in rat hepatic stellate cells]
Liver Cirrhosis, Alcoholic
Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis.
Liver Cirrhosis, Biliary
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Liver Diseases
A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study.
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease.
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.
Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.
Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity.
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
Effect of curcumin on visfatin and zinc-?2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.
Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease.
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway.
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Serum visfatin in nonalcoholic fatty liver disease.
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Visfatin Induces Inflammation and Insulin Resistance via the NF-?B and STAT3 Signaling Pathways in Hepatocytes.
Visfatin levels in nonalcoholic Fatty liver disease.
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
[Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease]
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Liver Diseases, Alcoholic
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Liver Neoplasms
Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells.
Inhibition of PI3K/Akt and ERK signaling decreases visfatin-induced invasion in liver cancer cells.
NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis.
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
The role of Visfatin and Resistin in an In Vitro Model of Obesity-Induced Invasive Liver Cancer.
Lung Diseases
Serum Adipokine Levels in Patients Considered for Lung Transplantation.
Serum Levels of Visfatin, Omentin and Irisin in Patients with End-Stage Lung Disease Before and After Lung Transplantation.
Lung Injury
Endothelial eNAMPT Amplifies Preclinical Acute Lung Injury: Efficacy of an eNAMPT-Neutralising mAb.
Inhibition of Pre-B Cell Colony Enhancing Factor Reduces Lung Injury in Rats Receiving Cardiopulmonary Bypass.
Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralization.
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.
Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in rats.
The NAMPT Promoter is Regulated by Mechanical Stress, STAT5, and ARDS-Associated Genetic Variants.
Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NF?B Signaling and Inflammatory Lung Injury.
Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown.
Visfatin Exerts Immunotherapeutic Effects in Lipopolysaccharide-Induced Acute Lung Injury in Murine Model.
Lung Neoplasms
An RNA-binding-protein, NONO governs energy metabolism by regulating NAMPT in lung cancer.
Evaluation of Serum Resistin, Visfatin, and Chemerin Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease.
NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer.
Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Lupus Erythematosus, Systemic
Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases.
Obesity in autoimmune diseases: not a passive bystander.
Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis.
The comparison of visfatin levels of gingival crevicular fluid in systemic lupus erythematosus and chronic periodontitis patients with healthy subjects.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Lymphatic Metastasis
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis.
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis.
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Lymphohistiocytosis, Hemophagocytic
Pre-B-cell colony-enhancing factor is markedly elevated in childhood hemophagocytic lymphohistiocytosis.
Lymphoma
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Lymphoma, B-Cell
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Lymphoma, Follicular
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Lymphoma, T-Cell, Cutaneous
Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.
Lymphopenia
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Macular Edema
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions.
Malnutrition
Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
Role of circulating adipocytokines vaspin, apelin, and visfatin in the loss of appetite in underweight children: a pilot trial.
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa.
Melanoma
A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.
Anti-angiogenic role of microRNA-23b in melanoma by disturbing NF-?B signaling pathway via targeted inhibition of NAMPT.
Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma ME45 cells.
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions.
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.
Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Sebocytes differentially express and secrete adipokines.
Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT).
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5).
The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells.
Viability and oxidative response of human colorectal HCT-116 cancer cells treated with visfatin/eNampt in vitro.
Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study.
[Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype].
Melanoma, Experimental
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5).
Memory Disorders
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Mesenteric Ischemia
The effect of serum, intestinal and peritoneal visfatin levels on early diagnosis of acute mesenteric ischemia.
Metabolic Diseases
Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes.
Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors.
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
The mRNA Expression and Circulating Levels of Visfatin and Their Correlation with Coronary Artery Disease Severity and 25-Hydroxyvitamin D.
Tripeptide IRW Upregulates NAMPT Protein Levels in Cells and Obese C57BL/6J Mice.
Visfatin as a novel mediator released by inflamed human endothelial cells.
Visfatin Triggers Anorexia and Body Weight Loss through Regulating the Inflammatory Response in the Hypothalamic Microglia.
Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders.
Metabolic Syndrome
Adipokines and cardiometabolic function: How are they interlinked?
Adiponectin and visfatin may serve as diagnosis markers for metabolic syndrome in Uygur population.
An evaluation of visfatin levels in obese subjects.
Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance.
Assessment of Metabolic Profile and Ischemia-modified Albumin Level in Patients with Alopecia Areata: A Case-Control Study.
Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities.
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome.
Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome.
Circulating visfatin levels in healthy preterm infants are independently associated with high-density lipoprotein cholesterol levels and dietary long-chain polyunsaturated fatty acids.
Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis.
Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome.
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Effects of 12 weeks of combined exercise training on visfatin and metabolic syndrome factors in obese middle-aged women.
Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.
Evaluation of irisin and visfatin levels in very low birth weight preterm newborns compared to full term newborns-A prospective cohort study.
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Hypothalamic ischemia and metabolic syndrome Comment to: Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Jerzy Bełtowski Med Sci Monit, 2006; 12(6): RA112-19.
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Increased plasma visfatin levels in subjects with the metabolic syndrome.
Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.
Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-? antagonist therapy.
Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin.
Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls.
Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome.
Relation of Adiponectin, Visfatin and Bone Mineral Density in patients with Metabolic Syndrome.
Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.
Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients.
Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome.
Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Serum visfatin levels and metabolic syndrome criteria in obese female subjects.
Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome.
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Study of visfatin expression in acne patients in tissue and serum.
The adipokine visfatin is markedly elevated in obese children.
The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome.
The correlation between insulin-like growth factor 1 (IGF-1) and novel adipocytokines in postmenopausal women: A population-based study.
The Impact of Type 2 Diabetes on Circulating Adipokines in Patients with Metabolic Syndrome.
The relationship between visfatin and cardiac markers on induced myocardial infarction in rats.
The relationship between visfatin and metabolic syndrome in postmenopausal women.
The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome.
The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women.
The release of the adipocytokine visfatin is regulated by glucose and insulin.
The role of Visfatin in atherosclerotic peripheral arterial obstructive disease.
The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis.
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Visfatin correlates with hot flashes in postmenopausal women with metabolic syndrome: effects of genistein.
Visfatin Enhances CXCL8, CXCL10, and CCL20 Production in Human Keratinocytes.
Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Visfatin induces MUC8 and MUC5B expression via p38 MAPK/ROS/NF-?B in human airway epithelial cells.
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study.
Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats.
[Inflammatory biomarkers: the link between obesity and associated pathologies]
Migraine Disorders
Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches.
Mucocutaneous Lymph Node Syndrome
Serum adipokine profiles in Kawasaki disease.
[Changes in serum levels of resistin and visfatin in pediatric patients with acute Kawasaki disease following intravenous immune globulin treatment].
Multiple Myeloma
Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity.
Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.
Multiple Sclerosis
Obesity in autoimmune diseases: not a passive bystander.
Peripheral levels of selected adipokines in patients with newly diagnosed multiple sclerosis.
Muscular Atrophy
Metabolomic and transcriptional profiling reveals bioenergetic stress and activation of cell death and inflammatory pathways in vivo after neuronal deletion of NAMPT.
Myasthenia Gravis
Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients.
Myocardial Infarction
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
An elevated plasma level of visfatin increases the risk of myocardial infarction.
Elevated serum visfatin levels in patients with acute myocardial infarction.
Increased expression of visfatin in monocytes and macrophages in male acute myocardial infarction patients.
Inhibition of Nicotinamide Phosphoribosyltransferase Reduces Neutrophil-Mediated Injury in Myocardial Infarction.
Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction.
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.
Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes.
Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls.
Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction.
The novel adipocytokine visfatin exerts direct cardioprotective effects.
The relationship between visfatin and cardiac markers on induced myocardial infarction in rats.
Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction.
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Myocardial Ischemia
Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction.
Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes.
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Visfatin and Cardio-Cerebro-Vascular Disease.
Myositis
Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients.
Neonatal Sepsis
Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis.
MiR-96-5p alleviates inflammatory responses by targeting NAMPT and regulating the NF-?B pathway in neonatal sepsis.
Neoplasm Metastasis
A Novel Role for the Adipokine Visfatin/Pre-B Cell Colony-enhancing Factor 1 in Prostate Carcinogenesis.
Cohesive cancer invasion of the biophysical barrier of smooth muscle.
Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.
Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors.
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis.
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis.
Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.
The role of metabolic syndrome variant in the malignant tumors progression.
The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis.
Visfatin increases miR-21 to promote migration in HCC.
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2.
Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.
Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway.
Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Neoplasms
A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
A H2S-Nampt dependent energetic circuit is critical to survival and cytoprotection from damage in cancer cells.
A new frame in thromboembolic cardiovascular disease: Adipocytokine.
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells.
A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study.
Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Adipokines and ?-cell dysfunction in normoglycemic women with previous gestational diabetes mellitus.
Adipokines and cardiometabolic function: How are they interlinked?
Adipokines and cytokines in non-alcoholic fatty liver disease.
Adipokines and Inflammation Alter the Interaction Between Rheumatoid Arthritis Synovial Fibroblasts and Endothelial Cells.
Adipokines and insulin resistance.
Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Adipokines demonstrate the interacting influence of central obesity with other cardiometabolic risk factors of metabolic syndrome in Hong Kong Chinese adults.
Adipokines in gestational diabetes.
Adipokines: the missing link between insulin resistance and obesity.
Adiponectin as a biomarker of the metabolic syndrome in children and adolescents.
Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.
Adiponectin: A biomarker for rheumatoid arthritis?
Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment.
Adipose Tissue as Regulator of Vascular Tone.
Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of dIabeteS in obese paTIeNts (The RESISTIN trial).
Adipose tissue, obesity and adipokines: role in cancer promotion.
Adipose Tissue: The New Endocrine Organ? A Review Article.
Advances in NAD-Lowering Agents for Cancer Treatment.
Aerobic Training Improves Angiogenic Potential Independently of Vascular Endothelial Growth Factor Modifications in Postmenopausal Women.
Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels.
An Overview of the Role of Adipokines in Cardiometabolic Diseases.
An Update on the Emerging Role of Visfatin in the Pathogenesis of Osteoarthritis and Pharmacological Intervention.
Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
Arylurea Derivatives: a Class of Potential Cancer Targeting Agents.
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients.
Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway.
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy.
Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Body mass index and adipokines/cytokines dysregulation in systemic sclerosis.
Boosted photocatalytic activity induced NAMPT-Regulating therapy based on elemental bismuth-humic acids heterojunction for inhibiting tumor proliferation/migration/inflammation.
Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA.
Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase.
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
CD73 Protein as a Source of Extracellular Precursors for Sustained NAD+ Biosynthesis in FK866-treated Tumor Cells.
Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells.
Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Chemotherapy and plasma adipokines level in patients with colorectal cancer.
Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk.
Circulating Serum Level of Visfatin in Patients with Endometrial Cancer.
Circulating visfatin in chronic obstructive pulmonary disease.
Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle.
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Circulating visfatin levels and cancers risk: A systematic review and meta-analysis.
Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.
Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
Cohesive cancer invasion of the biophysical barrier of smooth muscle.
Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients.
Comparison of adipose tissue derived genes in endogenous Cushing's syndrome versus diet-induced obesity.
Comparison of the effects of short-term hypolipidaemic treatment on plasma adipokine levels in men and women with isolated hypercholesterolaemia.
Correlation of serum adipocytokine levels with glycolipid metabolism and inflammatory factors in obese patients with periodontal disease.
Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
Crystal structure-based comparison of two NAMPT inhibitors.
Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.
Dedifferentiation of cancer cells following recovery from a potentially lethal damage is mediated by H2S-Nampt.
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Derivatization of the tricarboxylic acid intermediates with O-benzylhydroxylamine for liquid chromatography-tandem mass spectrometry detection.
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
Diet-induced obesity potentiates the growth of gastric cancer in mice.
Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop.
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Dingxin recipe alleviates atherosclerosis injury in ApoE-knockout mice via downregulation of visfatin expression and inhibition of the visfatin-induced inflammatory response.
Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells.
Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
DUAL NAMPT AND BTK TARGETING LEADS TO SYNERGISTIC KILLING OF WALDENSTROM`S MACROGLOBULINEMIA CELLS REGARDLESS OF MYD88 AND CXCR4 SOMATIC MUTATIONS STATUS.
Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Echocardiographic epicardial adipose tissue measurements provide information about cardiovascular risk in hemodialysis patients.
Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice.
Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
Effects of small interfering RNA targeting TLR4 on expressions of adipocytokines in obstructive sleep apnea hyponea syndrome with hypertension in a rat model.
Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-?, and Interleukin-6 in Gingival Crevicular Fluid in Patients with Type 2 Diabetes and Chronic Periodontitis.
Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients.
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters.
Elevated visfatin levels in obese children are related to proinflammatory factors.
Emerging Role of Adipocytokines in Type 2 Diabetes as Mediators of Insulin Resistance and Cardiovascular Disease.
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study.
Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer.
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.
Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
Extracellular NAMPT/visfatin causes p53 deacetylation via NAD production and SIRT1 activation in breast cancer cells.
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine.
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Filifactor alocis and Tumor Necrosis Factor-Alpha Stimulate Synthesis of Visfatin by Human Macrophages.
FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.
Fragment-based discovery of a potent NAMPT inhibitor.
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish.
Genetic predisposition to acute kidney injury induced by severe sepsis.
Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.
Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Handgrip strength, tumor necrosis factor-?, interlukin-6, and visfatin levels in oldest elderly patients with cognitive impairment.
HDAC Inhibitor Sodium Butyrate Augments the MEF2C Enhancement of Nampt Expression under Hypoxia.
High Leptin/Adiponectin Ratio and Serum Triglycerides Are Associated With an "At-Risk" Phenotype in Young Severely Obese Patients.
High level of visfatin and the activation of Akt and ERK1/2 signaling pathways are associated with endometrium malignant transformation in polycystic ovary syndrome.
High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival.
High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Hypothalamic ischemia and metabolic syndrome Comment to: Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Jerzy Bełtowski Med Sci Monit, 2006; 12(6): RA112-19.
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation.
Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Identification of the Nicotinamide Salvage Pathway as a New Toxification Route for Antimetabolites.
Impact of 14-day bed rest on serum adipokines and low-grade inflammation in younger and older adults.
Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative.
Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.
Increased levels and adipose tissue expression of visfatin in morbidly obese women. The relationship with pro-inflammatory cytokines.
Increased Nicotinamide Phosphoribosyltransferase and Cystathionine-?-Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma.
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events.
Increased Serum Levels of Tumor Necrosis Factor-Alpha, Resistin, and Visfatin in the Children with Autism Spectrum Disorders: A Case-Control Study.
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes.
Inflammation and fatness in adolescents with and without Down syndrome: UP & DOWN study.
Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma.
Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Inhibition of Nicotinamide Phosphoribosyltransferase Induces Apoptosis in Estrogen Receptor-Positive MCF-7 Breast Cancer Cells.
Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool.
Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans.
Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.
Intrauterine growth restriction and adult disease: the role of adipocytokines.
Investigating the effect of visfatin on ERalpha phosphorylation (Ser118 and Ser167) and ERE-dependent transcriptional activity.
Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes.
Is peritoneal dialysis causing a measurable burden of inflammatory and endothelial injury on top of metabolic syndrome?
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Laparoscopic sleeve gastrectomy induces molecular changes in peripheral white blood cells.
Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease.
Lipases and lipid droplet-associated protein expression in subcutaneous white adipose tissue of cachectic patients with cancer.
Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
Maternal leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha in normal and gestational diabetes.
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma.
Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors.
Melatonin reduces obesity and restores adipokine patterns and metabolism in obese (ob/ob) mice.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.
Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.
Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells.
MicroRNA Mediate Visfatin and Resistin Induction of Oxidative Stress in Human Osteoarthritic Synovial Fibroblasts Via NF-?B Pathway.
MicroRNA-494 induces breast cancer cell apoptosis and reduces cell viability by inhibition of nicotinamide phosphoribosyltransferase expression and activity.
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.
Modulation of cardiovascular function by adipokines.
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents.
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
NAD Metabolism in Cancer Therapeutics.
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.
NAD+ metabolism controls growth inhibition by HIF1 in normoxia and determines differential sensitivity of normal and cancer cells.
NAD+ metabolism controls inflammation during senescence.
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.
NAD+ metabolism, stemness, the immune response, and cancer.
NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples.
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance.
NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by ?-lapachone.
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Nampt is involved in DNA double-strand break repair.
NAMPT is the cellular target of STF-31-like small-molecule probes.
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.
NAMPT regulates PKM2 nuclear location through 14-3-3?: Conferring resistance to tamoxifen in breast cancer.
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.
NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Nampt/PBEF/visfatin and cancer.
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors.
NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
Nampt: linking NAD biology, metabolism and cancer.
New concepts in white adipose tissue physiology.
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology.
Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target.
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells.
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
Nicotinamide Phosphoribosyltransferase (NAMPT) acts as a metabolic gate for mobilization of myeloid-derived suppressor cells.
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience.
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.
Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages.
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders.
Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation.
Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle-dependent in mammalian cells, and its inhibition slows cell growth.
Obesity in chronic kidney disease: good or bad?
Obesity Potentiates Esophageal Squamous Cell Carcinoma Growth and Invasion by AMPK-YAP Pathway.
Optimization and bioactivity verification of porcine recombinant visfatin with high expression and low endotoxin content using pig liver as template.
Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents.
Physical activity and adipokine levels in individuals with type 2 diabetes: A literature review and practical applications.
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Physiological, pathological and potential therapeutic roles of adipokines.
Plasma and myocardial visfatin expression changes are associated with therapeutic hypothermia protection during murine hemorrhagic shock/resuscitation.
Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome.
Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium.
Preclinical Assessment of the ADME, Efficacy and Drug-Drug Interaction Potential of a Novel NAMPT Inhibitor.
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women.
Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis.
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy.
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.
Reviews: adipocytokines in normal and complicated pregnancies.
Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease.
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach.
Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target.
Role of visfatin in promoting proliferation and invasion of colorectal cancer cells by downregulating SDF-1/CXCR4-mediated miR-140-3p expression.
Roles and mechanisms of adipokines in drug resistance of tumor cells.
Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis.
Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-?B activity and affects Nampt-dependent cell viability in Huh-7 cells.
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Serum adipokine concentrations in dogs with diabetes mellitus: a pilot study.
Serum amyloid A - A prime candidate for identification of neonatal sepsis.
Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease.
Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis.
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism.
Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-?) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
Significance of Some Non-Invasive Biomarkers in the Early Diagnosis and Staging of Egyptian Breast Cancer Patients.
SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells.
Sleep duration, cardiovascular disease, and proinflammatory biomarkers.
Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Structural basis for resistance to diverse classes of NAMPT inhibitors.
Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors.
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Structure-based virtual screening, molecular dynamics simulation and in vitro evaluation to identify inhibitors against NAMPT.
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation.
Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
The ?-NAD
The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo.
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD(+) Depletion-Mediated Cytotoxicity.
The association between clinically suspect arthralgia and adipokines in obese patients.
The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes.
The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer.
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5).
The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer.
The Effect of Onion Peel Extract on Inflammatory Mediators in Korean Overweight and Obese Women.
The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia.
The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus.
The effects of fat distribution and some adipokines on insulin resistance.
The effects of physical activity on adipokines in individuals with overweight/obesity across the lifespan: A narrative review.
The Impact of CDH13 Polymorphism and Statin Administration on TG/HDL Ratio in Cardiovascular Patients.
The metabolic syndrome and adipocytokines.
The NAD(+) salvage pathway modulates cancer cell viability via p73.
The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis.
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells.
The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression.
The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer.
The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus.
The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome.
The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat.
The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
The role of extracellular and intracellular nicotinamide phosphoribosyl-transferase in cancer: diagnostic and therapeutic perspectives and challenges.
The role of metabolic syndrome variant in the malignant tumors progression.
The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis.
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
Treatment of Cancer with NAMPT Inhibitors.
Tumor Metabolic Reprogramming by Adipokines as a Critical Driver of Obesity-Associated Cancer Progression.
Tumor necrosis factor-? enhances hyperbaric oxygen-induced visfatin expression via JNK pathway in human coronary arterial endothelial cells.
Unravelling the Role of LncRNA WT1-AS/miR-206/NAMPT Axis as Prognostic Biomarkers in Lung Adenocarcinoma.
Up-regulation of miR-381 inhibits NAD+ salvage pathway and promotes apoptosis in breast cancer cells.
Upregulation of the adipokine genes ADIPOR1 and SPP1 is related to poor survival outcomes in colorectal cancer.
Utilization of 18F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo.
Visfatin and endothelial function in dialyzed patients.
Visfatin and global histone H3K9me levels in colon cancer.
Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization.
Visfatin effects on telomerase gene expression in AGS gastric cancer cell line.
Visfatin Enhances the Production of Cathelicidin Antimicrobial Peptide, Human ?-Defensin-2, Human ?-Defensin-3, and S100A7 in Human Keratinocytes and Their Orthologs in Murine Imiquimod-Induced Psoriatic Skin.
Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway.
Visfatin expression in subcutaneous adipose tissue of pre-menopausal women: relation to hormones and weight reduction.
Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF-?B signaling.
Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue.
Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway.
Visfatin induces sickness responses in the brain.
Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia.
Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis.
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Visfatin Levels in Behcet's Disease.
Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer.
Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2.
Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer.
Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.
Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL-17.
Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway.
Visfatin regulates the production of lipopolysaccharide-induced inflammatory cytokines through p38 signaling in murine macrophages.
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-?B/IL-6 signals.
Visfatin, a potential biomarker and prognostic factor for endometrial cancer.
[Adipocytokines as mediators of metabolic role of adipose tissue].
[Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis]
[Adipose tissue as an endocrine organ].
[Effects of FK866 on migration of A549 cells and related mechanism].
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
[FK866 protects polymicrobial sepsis-induced liver injury in mice].
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].
[SECRETORY FUNCTION OF WHITE ADIPOSE TISSUE AND ADIPOKINES: BIOLOGICAL EFFECTS AND CLINICAL SIGNIFICANCE (REVIEW)].
[The research advances in the relationship between visfatin and cancer].
[The role of the fat tissue and its hormones in the mechanisms of insulin resistance and the development of type 2 diabetes mellitus]
Neoplasms, Squamous Cell
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Neuralgia
Does Serum Visfatin Represent a Biochemical Marker to an Experimental Peripheral Neuropathic Pain in Mice.
Neuroblastoma
Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells.
Neurodegenerative Diseases
Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease.
Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment.
Nicotinamide phosphoribosyltransferase?related signaling pathway in early Alzheimer's disease mouse models.
Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis.
Neuroectodermal Tumors, Primitive
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Neuroendocrine Tumors
Extracellular Nampt (eNampt/Visfatin/PBEF) directly and indirectly stimulates ACTH and CCL2 protein secretion from isolated rat corticotropes.
NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
Neuroinflammatory Diseases
Metabolomic and transcriptional profiling reveals bioenergetic stress and activation of cell death and inflammatory pathways in vivo after neuronal deletion of NAMPT.
NAMPT and BMAL1 Are Independently Involved in the Palmitate-Mediated Induction of Neuroinflammation in Hypothalamic Neurons.
NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation.
Nicotinamide phosphoribosyltransferase secreted from microglia via exosome during ischemic injury.
Neutropenia
GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling.
NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.
nicotinamide phosphoribosyltransferase deficiency
Adipose tissue NAD+ biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice.
Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals.
Nicotinamide phosphoribosyltransferase (Nampt) may serve as the marker for osteoblast differentiation of bone marrow-derived mesenchymal stem cells.
Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP.
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Non-alcoholic Fatty Liver Disease
A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study.
Adipokines and cytokines in non-alcoholic fatty liver disease.
Adipokines in nonalcoholic fatty liver disease.
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease.
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.
Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.
Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
Effect of curcumin on visfatin and zinc-?2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease.
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway.
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease.
Serum visfatin in nonalcoholic fatty liver disease.
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
Visfatin Induces Inflammation and Insulin Resistance via the NF-?B and STAT3 Signaling Pathways in Hepatocytes.
Visfatin levels in nonalcoholic Fatty liver disease.
[Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease]
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
[The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease]
Non-Radiographic Axial Spondyloarthritis
Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.
Obesity
A Common Haplotype in NAPEPLD Is Associated With Severe Obesity in a Norwegian Population-Based Cohort (the HUNT Study).
A novel adipocytokine visfatin protects against H(2)O(2) -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease.
A novel single-nucleotide polymorphism of the visfatin gene and its associations with performance traits in the chicken.
A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity.
A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis.
ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity.
Acute and Chronic Effects of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Visfatin and Apelin Levels in Patients with Severe Obesity.
Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
Adipokine Visfatin's Role in Pathogenesis of Diabesity and Related Metabolic Derangements.
Adipokines and etiopathology of metabolic disorders.
Adipokines Vaspin and Visfatin in Obese Children.
Adiponectin Signaling and Impaired GTPase Rab5 Expression in Adipocytes of Adolescents with Obesity.
Adiponectin, Leptin and Visfatin in Hypoxia and its Effect for Weight Loss in Obesity.
Adipose tissue, obesity and adipokines: role in cancer promotion.
An evaluation of visfatin levels in obese subjects.
An Overview of the Role of Adipokines in Cardiometabolic Diseases.
An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity.
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Association of adipokines with obesity in children and adolescents.
Association of genetic variability in selected regions in visfatin (NAMPT) gene with anthropometric parameters and dietary composition in obese and non-obese Central-European population.
Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity.
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Associations between Adipokines in Arthritic Disease and Implications for Obesity.
Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity?
Body fat distribution has no effect on serum visfatin levels in healthy female subjects.
Body mass index and adipokines/cytokines dysregulation in systemic sclerosis.
Can adipokine visfatin be a novel marker of pregnancy-related disorders in women with obesity?
Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus.
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Common variants in LEPR, IL6, AMD1, and NAMPT do not associate with risk of juvenile and childhood obesity in Danes: a case-control study.
Comparing the prolonged effect of interval versus continuous aerobic exercise on blood inflammatory marker of Visfatin level and body mass index of sedentary overweigh/fat female college students.
Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion.
Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop.
Dietary and physical activity patterns in children with obstructive sleep apnea.
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Differential Expression of Human N-Alpha-Acetyltransferase 40 (hNAA40), Nicotinamide Phosphoribosyltransferase (NAMPT) and Sirtuin-1 (SIRT-1) Pathway in Obesity and T2DM: Modulation by Metformin and Macronutrient Intake.
Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism.
Do novel adipokines play a causative or only modulating role in the pathogenesis of obesity and metabolic disorders?
Editorial.
Effect of exercise training on plasma visfatin and eotaxin levels.
Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
Effect of simvastatin treatment on plasma visfatin levels in obese women.
Effects of 12 weeks of combined exercise training on visfatin and metabolic syndrome factors in obese middle-aged women.
Effects of Diet-Induced Obesity on Tracheal Responsiveness to Methacholine, Tracheal Visfatin Level, and Lung Histological Changes in Ovalbumin-Sensitized Female Wistar Rats.
Effects of fatty acid regulation on visfatin gene expression in adipocytes.
Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children.
Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.
Effects of visfatin on brown adipose tissue energy regulation using T37i cells.
Elevated 1-hour post-load plasma glucose identifies obese youth with abnormal glucose metabolism and an unfavorable inflammatory profile.
Elevated microRNA-34a in obesity reduces NAD(+) levels and SIRT1 activity by directly targeting NAMPT.
Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Elevated vaspin and leptin levels are associated with obesity in prepubertal Korean children.
Elevated visfatin levels in obese children are related to proinflammatory factors.
Endothelial NLRP3 Inflammasome Activation and Enhanced Neointima Formation in Mice by Adipokine Visfatin.
Ethnic-specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function.
Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Experimental obesity and diabetes reduce male fertility: Potential involvement of hypothalamic Kiss-1, pituitary nitric oxide, serum vaspin and visfatin.
Exploring the Crosstalk between Hydrostatic Pressure and Adipokines: An In Vitro Study on Human Osteoarthritic Chondrocytes.
Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism.
Fasting- and ghrelin-induced food intake is regulated by NAMPT in the hypothalamus.
Functional effects of visfatin in isolated rat mesenteric small resistance arteries.
Genetic associations of the visfatin G-948T polymorphism with obesity-related metabolic traits in an Iranian population.
Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population.
Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans.
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Impact of metabolic regulators on the expression of the obesity associated genes FTO and NAMPT in human preadipocytes and adipocytes.
Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats.
In Vivo and Ex Vivo Regulation of Visfatin Production by Leptin in Human and Murine Adipose Tissue: Role of MAPK and PI3-K Signalling Pathways.
Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.
Increased Visfatin Expression Is Associated with Nuclear Factor-?B in Obese Ovalbumin-Sensitized Male Wistar Rat Tracheae.
Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin.
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose.
Instigation of endothelial Nlrp3 inflammasome by adipokine visfatin promotes inter-endothelial junction disruption: role of HMGB1.
Insulin-like effects of visfatin on human osteoblasts.
Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors.
Investigating the effect of visfatin on ERalpha phosphorylation (Ser118 and Ser167) and ERE-dependent transcriptional activity.
Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models.
Lack of effect of a moderate hypocaloric diet on visfatin levels in morbid obese patients: relationship with insulin resistance.
Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans.
Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes.
Liver X Receptor (LXR) activation negatively regulates visfatin expression in macrophages.
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin.
Maternal visfatin concentration in normal pregnancy.
MC4R Variant rs17782313 Associates With Increased Levels of DNAJC27, Ghrelin, and Visfatin and Correlates With Obesity and Hypertension in a Kuwaiti Cohort.
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Molecular characteristics of serum visfatin and differential detection by immunoassays.
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
NAMPT-mediated NAD
Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
Nicotinamide Phosphoribosyltransferase (Nampt)/Nicotinamide Adenine Dinucleotide (NAD) Axis Suppresses Atrial Fibrillation by Modulating the Calcium Handling Pathway.
Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation.
Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.
Obesity and obstructive sleep apnea syndrome.
Obesity in autoimmune diseases: not a passive bystander.
Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome.
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Plasma concentration and expression of adipokines in epicardial and subcutaneous adipose tissue are associated with impaired left ventricular filling pattern.
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.
Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass.
Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.
Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome.
Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome.
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.
Regulation of adipokine secretion by n-3 fatty acids.
Regulation of regenerative periodontal healing by NAMPT.
Regulation of visfatin by microbial and biomechanical signals in PDL cells.
Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans.
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Risk analysis of systemic levels of estrogen and adipokines as well as estrogen receptors from PBMCs in childbearing and perimenopausal women with obesity.
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach.
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Serum concentration of visfatin in obese women.
Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity.
Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome.
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism.
Serum visfatin concentration and its relationship with sex hormones in obese Saudi women.
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Serum visfatin levels and metabolic syndrome criteria in obese female subjects.
Serum visfatin levels in a group of Egyptian obese individuals.
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa.
Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-?) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
Sleep Deficiency is a Modifiable Risk Factor for Obesity and Cognitive Impairment and Associated with Elevated Visfatin.
Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells.
Strong association of the polymorphisms in PBEF1 and knee OA risk: a two-stage population-based study in China.
The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion.
The association between clinically suspect arthralgia and adipokines in obese patients.
The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
The FTO Obesity Gene. Genotyping and Gene Expression Analysis in Morbidly Obese Patients.
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
The relationship between visfatin and cardiac markers on induced myocardial infarction in rats.
The role of adipokines in periodontal infection and healing.
The role of Visfatin and Resistin in an In Vitro Model of Obesity-Induced Invasive Liver Cancer.
The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis.
The role of visfatin in diabetic nephropathy.
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
The up-regulation of markers of adipose tissue fibrosis by visfatin in pre-adipocytes as well as obese children and adolescents.
The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects.
TNF-alpha alters visfatin and adiponectin levels in human fat.
Tumor Metabolic Reprogramming by Adipokines as a Critical Driver of Obesity-Associated Cancer Progression.
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Visfatin and its role in obesity development.
Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome.
Visfatin and SREBP-1c mRNA Expressions and Serum Levels Among Egyptian Women with Polycystic Ovary Syndrome.
Visfatin as a therapeutic target for rheumatoid arthritis.
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism.
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.
Visfatin induces MUC8 and MUC5B expression via p38 MAPK/ROS/NF-?B in human airway epithelial cells.
Visfatin induces sickness responses in the brain.
Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NF?B and JNK in human abdominal subcutaneous adipocytes.
Visfatin levels in prepubertal children born small or large for gestational age.
Visfatin Promotes Monocyte Adhesion by Upregulating ICAM-1 and VCAM-1 Expression in Endothelial Cells via Activation of p38-PI3K-Akt Signaling and Subsequent ROS Production and IKK/NF-?B Activation.
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Visfatin Triggers Anorexia and Body Weight Loss through Regulating the Inflammatory Response in the Hypothalamic Microglia.
Visfatin, low-grade inflammation and body mass index (BMI).
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Visfatin--a review.
Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders.
Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
Visfatin: the missing link between intra-abdominal obesity and diabetes?
Weighted gene co-expression network analysis of expression data of monozygotic twins identifies specific modules and hub genes related to BMI.
[Adipocytokines: potential biomarkers for childhood obesity and anorexia nervosa?]
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
[Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female].
[Effects of visfatin gene polymorphisms on glycolipid metabolism and exercise-induced weight reduction in obesity].
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Novel adipokines: links between obesity and atherosclerosis].
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].
[The research advances in the relationship between visfatin and cancer].
[The role of visfatin in the pathophysiology of human]
Obesity, Abdominal
An evaluation of visfatin levels in obese subjects.
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Effect of exercise training on plasma visfatin and eotaxin levels.
Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
Ethnic-specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function.
High-density lipoprotein inhibits ox-LDL-induced adipokine secretion by upregulating SR-BI expression and suppressing ER Stress pathway.
Metabolic effects associated with adipose tissue distribution.
The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity.
The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women.
The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Obesity, Morbid
A Common Haplotype in NAPEPLD Is Associated With Severe Obesity in a Norwegian Population-Based Cohort (the HUNT Study).
A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity.
Acute and Chronic Effects of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Visfatin and Apelin Levels in Patients with Severe Obesity.
C-peptide modifies leptin and visfatin secretion in human adipose tissue.
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Obstetric Labor, Premature
Evidence for differential regulation of the adipokine visfatin in the maternal and fetal compartments in normal spontaneous labor at term.
Maternal plasma visfatin in preterm labor.
The role of visfatin (PBEF/Nampt) in pregnancy complications.
Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.
Osteoarthritis
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee.
An extensive review regarding the adipokines in the pathogenesis and progression of osteoarthritis.
An Update on the Emerging Role of Visfatin in the Pathogenesis of Osteoarthritis and Pharmacological Intervention.
Associations between Adipokines in Arthritic Disease and Implications for Obesity.
Can adipokines serum levels be used as biomarkers of hand osteoarthritis?
Circulating levels of adiponectin, resistin, and visfatin after mud-bath therapy in patients with bilateral knee osteoarthritis.
Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis.
Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis.
Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis.
Melatonin inhibits Sirt1-dependent NAMPT and NFAT5 signaling in chondrocytes to attenuate osteoarthritis.
NAMPT (visfatin), a direct target of hypoxia-inducible factor-2?, is an essential catabolic regulator of osteoarthritis.
Pro-inflammatory actions of visfatin/Nampt involve regulation of insulin signaling pathway and Nampt enzymatic activity.
Reciprocal regulation by hypoxia-inducible factor-2? and the NAMPT-NAD(+)-SIRT axis in articular chondrocytes is involved in osteoarthritis.
Strong association of the polymorphisms in PBEF1 and knee OA risk: a two-stage population-based study in China.
The current progress in understanding the molecular functions and mechanisms of visfatin in osteoarthritis.
The Effects of Adipokines on Cartilage and Meniscus Catabolism.
Visfatin alters the cytokine and matrix-degrading enzyme profile during osteogenic and adipogenic MSC differentiation.
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Visfatin increases ICAM-1 expression and monocyte adhesion in human osteoarthritis synovial fibroblasts by reducing miR-320a expression.
Visfatin Increases VEGF-dependent Angiogenesis of Endothelial Progenitor Cells during Osteoarthritis Progression.
[The nicotinamide-phosphoribosiltransferase as a marker of systemic inflammation under osteoarthrosis.]
Osteoarthritis, Hip
eNAMPT Is Localised to Areas of Cartilage Damage in Patients with Hip Osteoarthritis and Promotes Cartilage Catabolism and Inflammation.
Osteoarthritis, Knee
Circulating levels of adiponectin, resistin, and visfatin after mud-bath therapy in patients with bilateral knee osteoarthritis.
Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis.
Synovial fluid adipokines are associated with clinical severity in knee osteoarthritis: a cross-sectional study in female patients with joint effusion.
Osteophyte
Expression of adipokines in osteoarthritis osteophytes and their effect on osteoblasts.
Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis.
Initial responses of articular tissues in a murine high-fat diet-induced osteoarthritis model: pivotal role of the IPFP as a cytokine fountain.
Osteoporosis
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Dietary fat intake associated with bone mineral density among visfatin genotype in obese people.
Epigenetic regulation of Runx2 transcription and osteoblast differentiation by nicotinamide phosphoribosyltransferase.
Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-?B ligand-induced osteoclast differentiation in vitro.
Research on the correlation of diabetes mellitus complicated with osteoporosis with lipid metabolism, adipokines and inflammatory factors and its regression analysis.
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
Visfatin alters the cytokine and matrix-degrading enzyme profile during osteogenic and adipogenic MSC differentiation.
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Osteoporosis, Postmenopausal
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
Osteosarcoma
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.
Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.
Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-?B/IL-6 signals.
Ovarian Neoplasms
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma ME45 cells.
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.
Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study.
Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization.
Overweight
Adenovirus36 infection expresses cellular APMI and Visfatin genes in overweight Uygur individuals.
Adipose tissue-derived cytokines and their correlations with clinical characteristics in Vietnamese patients with type 2 diabetes mellitus.
Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity.
Comparing the prolonged effect of interval versus continuous aerobic exercise on blood inflammatory marker of Visfatin level and body mass index of sedentary overweigh/fat female college students.
Effect of substituting saturated with monounsaturated fatty acids on serum visfatin levels and insulin resistance in overweight women: A randomized cross-over clinical trial.
Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats.
Effects of increased physical activity and/or weight loss diet on serum myokine and adipokine levels in overweight adults with impaired glucose metabolism.
Elevated vaspin and leptin levels are associated with obesity in prepubertal Korean children.
Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.
in vivo Suppression of Visfatin by Oral Glucose Uptake: Evidence for a Novel Incretin-Like Effect by Glucagon-Like Peptide-1 (GLP-1).
Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome.
Plasma visfatin level in women with polycystic ovary syndrome.
Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Relationship of visfatin level to pancreatic endocrine hormone level, HOMA-IR index, and HOMA ?-cell index in overweight women who performed hydraulic resistance exercise.
Resistance training increases muscle NAD+ and NADH concentrations as well as NAMPT protein levels and global sirtuin activity in middle-aged, overweight, untrained individuals.
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
SERUM BILIRUBIN CORRELATES WITH SERUM ADIPOKINES IN NORMAL WEIGHT AND OVERWEIGHT ASYMPTOMATIC ADULTS.
Serum visfatin concentration and its relationship with sex hormones in obese Saudi women.
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Study of visfatin expression in acne patients in tissue and serum.
Visfatin as a predictor for growth of fetus and infant.
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Visfatin, low-grade inflammation and body mass index (BMI).
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Visfatin, TNF-alpha and IL-6 mRNA Expression is Increased in Mononuclear Cells from Type 2 Diabetic Women.
Pancreatic Neoplasms
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Pancreatitis
Admission Visfatin Levels Predict Pancreatic and Peripancreatic Necrosis in Acute Pancreatitis and Correlate With Clinical Severity.
Circulating levels of visfatin, resistin and pro-inflammatory cytokine interleukin-8 in acute pancreatitis.
Inhibition of nicotinamide phosphoribosyltransferase protects against acute pancreatitis via modulating macrophage polarization and its related metabolites.
Obesity and the risk of severe acute pancreatitis.
Pancreatitis, Alcoholic
Inhibition of nicotinamide phosphoribosyltransferase protects against acute pancreatitis via modulating macrophage polarization and its related metabolites.
Paralysis
Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death.
Metabolomic and transcriptional profiling reveals bioenergetic stress and activation of cell death and inflammatory pathways in vivo after neuronal deletion of NAMPT.
Parkinson Disease
Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease.
Pediatric Obesity
Adipocytokine levels in children: effects of fatness and training.
Adiponectin, Resistin, and Visfatin in Childhood Obesity and Exercise.
Common variants in LEPR, IL6, AMD1, and NAMPT do not associate with risk of juvenile and childhood obesity in Danes: a case-control study.
Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices.
Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol.
The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Visfatin: the link between inflammation and childhood obesity.
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Pemphigus
The effect of l-carnitine supplementation on serum levels of omentin-1, visfatin and SFRP5 and glycemic indices in patients with pemphigus vulgaris: A randomized, double-blind, placebo-controlled clinical trial.
Peri-Implantitis
Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study.
Pericarditis
Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: biomarkers of disease activity? A preliminary report.
Periodontal Diseases
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Comparative Evaluation of Salivary Visfatin Levels in Healthy and Periodontally Diseased Patients before and after Scaling and Root Planing.
Correlation of serum adipocytokine levels with glycolipid metabolism and inflammatory factors in obese patients with periodontal disease.
Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease.
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Evaluation of association between Porphyromonas gingivalis and visfatin levels in chronic periodontitis patients.
Filifactor alocis and Tumor Necrosis Factor-Alpha Stimulate Synthesis of Visfatin by Human Macrophages.
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome.
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Salivary Visfatin Concentration in Response to Non-surgical Periodontal Therapy.
The Role of Visfatin (Adipocytokine) Biomarker in Oral Health and Diseases among Nonobese Indian Population: A Proteomic Assay.
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Visfatin levels in gingival crevicular fluid and serum before and after non-surgical treatment for periodontal diseases.
Periodontal Pocket
Porphyromonas gingivalis and Epstein-Barr Virus Are Associated With Increased Levels of Visfatin in Gingival Crevicular Fluid.
Periodontitis
Effect of non-surgical periodontal treatment on three salivary adipokines in diabetic patients with periodontitis.
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study.
Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation.
Filifactor alocis and Tumor Necrosis Factor-Alpha Stimulate Synthesis of Visfatin by Human Macrophages.
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
NAMPT enzyme activity regulates catabolic gene expression in gingival fibroblasts during periodontitis.
Non-Surgical Periodontal Therapy Reduces Saliva Adipokines and Matrix Metalloproteinases Levels in Periodontitis.
Periodontitis contributes to aberrant metabolism in type 2 diabetes mellitus rats by stimulating the expression of adipokines.
Porphyromonas gingivalis and Epstein-Barr Virus Are Associated With Increased Levels of Visfatin in Gingival Crevicular Fluid.
Regulation of NAMPT in Human Gingival Fibroblasts and Biopsies.
Regulation of regenerative periodontal healing by NAMPT.
Regulation of visfatin by microbial and biomechanical signals in PDL cells.
Salivary Visfatin Concentration in Chronic Periodontitis Patients.
Salivary Visfatin Concentration in Response to Non-surgical Periodontal Therapy.
Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells.
The role of adipokines in periodontal infection and healing.
The Role of Visfatin (Adipocytokine) Biomarker in Oral Health and Diseases among Nonobese Indian Population: A Proteomic Assay.
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: An immunohistochemical analysis.
Visfatin regulates Pg LPS-induced proinflammatory/prodegradative effects in healthy and inflammatory periodontal cells partially via NF-?B pathway.
Peripheral Nervous System Diseases
Dysregulation of NAD+ Metabolism Induces a Schwann Cell Dedifferentiation Program.
Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy.
Pheochromocytoma
Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway.
Pneumonia
Elevated plasma visfatin concentrations in patients with community-acquired pneumonia.
The Association of Chlamydia pneumonia and Helicobacter pylori IgG Seropositivity With Omentin-1, Visfatin and Adiponectin Levels in Postmenopausal Women.
Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown.
Visfatin Exerts Immunotherapeutic Effects in Lipopolysaccharide-Induced Acute Lung Injury in Murine Model.
Visfatin levels in patients with severe pneumonia.
Polycystic Ovary Syndrome
Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation.
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Effect of Omega-3 Supplementation on Visfatin, Adiponectin, and Anthropometric Indices in Women with Polycystic Ovarian Syndrome.
Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome.
Evidence for serum visfatin but not adiponectin or resistin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome.
Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome.
Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome.
High level of visfatin and the activation of Akt and ERK1/2 signaling pathways are associated with endometrium malignant transformation in polycystic ovary syndrome.
High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis.
Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis.
Increased plasma visfatin concentrations in women with polycystic ovary syndrome.
Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin.
Is there association between vitamin D levels, apelin 36, and visfatin in PCOS?
Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels.
Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome.
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Plasma visfatin level in women with polycystic ovary syndrome.
Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome.
Plasma Visfatin Levels in Adolescents with Polycystic Ovary Syndrome: A Prospective Case-Control Study.
Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome.
Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome.
Serum visfatin in Asian women with polycystic ovary syndrome.
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Serum visfatin is elevated in Chinese women with polycystic ovary syndrome, but might not be a reliable predictor of their glucose intolerance.
Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls.
Serum visfatin levels in women with polycystic ovary syndrome.
Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome.
Spleen-yang-deficiency patients with polycystic ovary syndrome have higher levels of visfatin.
Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation.
Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome.
Visfatin and SREBP-1c mRNA Expressions and Serum Levels Among Egyptian Women with Polycystic Ovary Syndrome.
[Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome]
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
[The research advances in the relationship between visfatin and cancer].
Polycythemia Vera
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Pre-Eclampsia
Adipokine Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy.
Association between circulating visfatin and pre-eclampsia: a systematic review and meta-analysis.
Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?
Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia.
Effect of intrauterine growth pattern on serum visfatin concentrations in full-term infants at birth and at 6 months of life.
Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Increased visfatin and leptin in pregnancies complicated by pre-eclampsia.
Maternal adiponectin and visfatin concentrations in normal and complicated pregnancies.
Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate.
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
NAMPT levels are inversely related to nitric oxide formation and positively related to soluble fms-like tyrosine kinase-1 levels in preeclampsia.
NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia.
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Serum adipocytokines and adiposity as predictive indices of preeclampsia.
Serum levels of the adipokine visfatin are increased in pre-eclampsia.
Serum visfatin levels in late pregnancy and pre-eclampsia.
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
The role of visfatin (PBEF/Nampt) in pregnancy complications.
Visfatin serum levels are increased in women with preeclampsia: A case-control study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Adipokines in young survivors of childhood acute lymphocytic leukemia revisited: beyond fat mass.
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.
Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.
Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia.
Prediabetic State
Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.
Plasma adiponectin, visfatin, leptin, and resistin levels and the onset of colonic polyps in patients with prediabetes.
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Pregnancy Complications
Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function.
The role of visfatin (PBEF/Nampt) in pregnancy complications.
Premature Birth
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Umbilical cord blood and maternal visfatin (PBEF/NAMPT) concentrations in preterm birth with and without preterm premature rupture of membranes.
Primary Myelofibrosis
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Prostatic Neoplasms
A Novel Role for the Adipokine Visfatin/Pre-B Cell Colony-enhancing Factor 1 in Prostate Carcinogenesis.
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.
Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target.
Proteinuria
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.
Psoriasis
Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities.
Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis.
Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis Vulgaris.
Circulating levels of Apelin 36 in patients with mild to moderate psoriasis.
Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis.
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis?
Mild to moderate psoriasis is associated with oxidative stress, subclinical atherosclerosis, and endothelial dysfunction.
Obesity in autoimmune diseases: not a passive bystander.
Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis".
Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers.
Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab.
Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-? inhibitors: results of a retrospective analysis.
Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity.
Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-?) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Visfatin Enhances CXCL8, CXCL10, and CCL20 Production in Human Keratinocytes.
Visfatin Enhances the Production of Cathelicidin Antimicrobial Peptide, Human ?-Defensin-2, Human ?-Defensin-3, and S100A7 in Human Keratinocytes and Their Orthologs in Murine Imiquimod-Induced Psoriatic Skin.
Pulmonary Arterial Hypertension
Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2?.
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase.
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.
Pulmonary Disease, Chronic Obstructive
Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease.
Circulating visfatin in chronic obstructive pulmonary disease.
Evaluation of Serum Resistin, Visfatin, and Chemerin Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease.
Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis.
Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease.
Serum levels of visfatin, sirtuin-1, and interleukin-6 in stable and acute exacerbation of chronic obstructive pulmonary disease.
The role of adipokines in the pathogenesis and course of selected respiratory diseases.
Visfatin levels in patients with severe pneumonia.
Purpura
Elevated serum levels of visfatin in patients with henoch-schönlein purpura.
Pyelonephritis
Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis.
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
Radiation Pneumonitis
Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralization.
Renal Insufficiency
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Renal Insufficiency, Chronic
Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.
Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.
Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes.
Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells.
Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study.
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels.
Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease.
Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients.
Reperfusion Injury
Adiponectin and resistin protect steatotic livers undergoing transplantation.
The function of nicotinamide phosphoribosyltransferase in the heart.
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Visfatin relieves myocardial ischemia-reperfusion injury through activation of PI3K/Akt/HSP70 signaling axis.
Respiratory Distress Syndrome
Clinical role of serum pre-B cell colony-enhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.
Novel Mechanism for Nicotinamide Phosphoribosyltransferase Inhibition of TNF-?-Mediated Apoptosis in Human Lung Endothelial Cells.
Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome.
[The influence of pre-B-cell colony enhancing factor on adhesive molecule in pulmonary cells in rats with acute lung injury/acute respiratory distress syndrome].
Retinal Diseases
Loss of NAMPT in aging retinal pigment epithelium reduces NAD+ availability and promotes cellular senescence.
Retinal Neovascularization
Visfatin promotes angiogenesis of RF/6A cells through upregulation of VEGF/VEGFR-2 under high-glucose conditions.
Retinopathy of Prematurity
IGF-I and Visfatin Levels in Retinopathy of Prematurity.
Rhabdomyosarcoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Rhabdomyosarcoma, Alveolar
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Rheumatic Diseases
Adipokines as emerging mediators of immune response and inflammation.
Adipokines in connective tissue diseases.
Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis.
The association between clinically suspect arthralgia and adipokines in obese patients.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
What's new in our understanding of the role of adipokines in rheumatic diseases?
[Adipocytokines: emerging mediators of the immune response and inflammation].
Rosacea
Sebocytes differentially express and secrete adipokines.
Sarcoidosis
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Sarcoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Sarcoma, Ewing
EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma.
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma.
Scleroderma, Diffuse
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
Scleroderma, Systemic
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis.
The role of adipokines in systemic sclerosis: a missing link?
Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis.
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Seizures
Acute Phase Serum Leptin, Adiponectin, Interleukin-6, and Visfatin Are Altered in Chinese Children With Febrile Seizures: A Cross-Sectional Study.
Seizures, Febrile
Acute Phase Serum Leptin, Adiponectin, Interleukin-6, and Visfatin Are Altered in Chinese Children With Febrile Seizures: A Cross-Sectional Study.
Sepsis
Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study.
Clinical role of serum pre-B cell colony-enhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome.
Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis.
Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury.
Essential Role of Visfatin in Lipopolysaccharide and Colon Ascendens Stent Peritonitis-Induced Acute Lung Injury.
Extracellular nicotinate phosphoribosyltransferase binds Toll like receptor 4 and mediates inflammation.
Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis.
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
microRNA-300/NAMPT regulates inflammatory responses through activation of AMPK/mTOR signaling pathway in neonatal sepsis.
MiR-96-5p alleviates inflammatory responses by targeting NAMPT and regulating the NF-?B pathway in neonatal sepsis.
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.
Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis.
The Role of Adipose Tissue and Adipokines in Sepsis: Inflammatory and Metabolic Considerations, and the Obesity Paradox.
Visfatin induces sickness responses in the brain.
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions.
Shock, Septic
Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study.
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
Short Bowel Syndrome
Ghrelin, visfatin and irisin in children with short bowel syndrome.
Sialadenitis
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Sleep Apnea Syndromes
Obesity and obstructive sleep apnea syndrome.
Sleep Apnea, Obstructive
Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea.
Coexistence of obstructive sleep apnea and telomerase activity, concentration of selected adipose tissue hormones and vascular endothelial function in patients with arterial hypertension.
Dietary and physical activity patterns in children with obstructive sleep apnea.
Visfatin as a predictor of obstructive sleep apnea in atrial fibrillation patients.
Sleep Deprivation
Sleep Deficiency is a Modifiable Risk Factor for Obesity and Cognitive Impairment and Associated with Elevated Visfatin.
Small Cell Lung Carcinoma
Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Spinal Cord Injuries
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Spondylitis, Ankylosing
Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-? antagonist therapy.
Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression.
The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis
Squamous Cell Carcinoma of Head and Neck
Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients.
Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
ST Elevation Myocardial Infarction
Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction.
Starvation
Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans.
Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.
Stomach Neoplasms
Adipocyte Derived Hormones Gene Expression, Resistin and Visfatin, in AGS Gastric Cancer Cell Line.
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer.
Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop.
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
High glucose promotes gastric cancer chemoresistance in vivo and in vitro.
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Synergistic Effects of Resistin and Visfatin as Adipocyte Derived Hormones on Telomerase Gene Expression in AGS Gastric Cancer Cell Line.
Visfatin effects on telomerase gene expression in AGS gastric cancer cell line.
Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF-?B signaling.
Stroke
Association of serum vaspin, apelin, and visfatin levels and stroke risk in a Chinese case-control study.
Cerebrovascular Disease: Consequences of Obesity-Induced Endothelial Dysfunction.
Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke.
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
NAMPT as a Therapeutic Target against Stroke.
Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway.
Prognostic significance of plasma visfatin levels in patients with ischemic stroke.
Selected adipose tissue hormones in the blood of patients with ischaemic cerebral stroke.
Targeting NAMPT as a therapeutic strategy against stroke.
The emerging role of leptin, Adiponectin and Visfatin in Ischemic/Hemorrhagic stroke.
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis.
Subarachnoid Hemorrhage
Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage.
Temporomandibular Joint Disorders
Analysis of synovial fluid visfatin level in temporomandibular joint disorders.
Thrombocythemia, Essential
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Thrombocytopenia
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Thyroid Cancer, Papillary
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Thyroid Diseases
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Thyroid Neoplasms
Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies.
Cystathione ?-Synthase Is Increased in Thyroid Malignancies.
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Thyroiditis
Role of Nampt overexpression in a rat model of Hashimoto's thyroiditis and its mechanism of action.
Thyroiditis, Autoimmune
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Visfatin level in children and adolescents with autoimmune thyroiditis.
Triple Negative Breast Neoplasms
Correction: Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Dezocine, An Opioid Analgesic, Exerts Antitumor Effects in Triple-Negative Breast Cancer by Targeting Nicotinamide Phosphoribosyltransferase.
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Optical Redox Imaging of Treatment Responses to Nampt Inhibition and Combination Therapy in Triple-Negative Breast Cancer Cells.
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Tuberculosis, Pulmonary
The mRNA expression of visfatin and lipocalin-2 in peripheral blood mononuclear cells from patients with pulmonary tuberculosis.
Uremia
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels.
Urinary Bladder Neoplasms
Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.
Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer.
Vascular Diseases
Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.
Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.
Visfatin, glucose metabolism and vascular disease: a review of evidence.
Ventilator-Induced Lung Injury
Endotoxin- and mechanical stress-induced epigenetic changes in the regulation of the nicotinamide phosphoribosyltransferase promoter.
Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury.
MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866.
Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration.
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.
Virus Diseases
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT.
Waldenstrom Macroglobulinemia
DUAL NAMPT AND BTK TARGETING LEADS TO SYNERGISTIC KILLING OF WALDENSTROM`S MACROGLOBULINEMIA CELLS REGARDLESS OF MYD88 AND CXCR4 SOMATIC MUTATIONS STATUS.